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Nor	 is	 there	 direct	 evidence	 for	 potentially	 controversial	 phenomena	 such	 as	 signalling	 bias	 in	
endogenous	cells.	This	provided	the	impetus	to	address	the	need	for	a	better	understanding	of	the	










they	 govern	 and	 dictate	 the	 intracellular	 signalling	 of	 the	 CGRP	 family	 of	 peptides	 endogenously.	
Beyond	 this,	 the	 G	 protein	 and	 accessory	 protein	 involvement	 in	 certain	 signalling	 cascades,	 the	
spatiotemporal	aspects	to	CGRP	peptide	signalling,	and	the	functional	outcomes	of	signalling	in	cell	
organoid	models	 are	 all	 explored.	 It	 is	 the	 author’s	 belief	 that	 this	work	 adds	 a	 great	 deal	 to	 the	











(e.g.	 muscarinic	 acetylcholine	 receptors)	 (Lefkowitz	 2004).	 Cell	 surface	 receptors	 can	 come	 into	
contact	with	the	external	environment,	internal	environment,	and	very	often	the	extracellular	matrix	
(ECM).	 Which	 is	 a	 non-cellular	 network	 made	 up	 of	 collagens,	 elastin,	 fibronectin,	 and	 other	
glycoproteins.	 The	matrix	 components	provide	a	 complex	network	 for	 cells	 to	 reside	 in	 tissues	by	
binding	 each	 other,	 matrix	 proteins	 and	 cell	 adhesion	 receptors	 (Theocharis	 et	 al.	 2016).	 The	
molecules	that	can	bind	and	invoke	a	reaction	in	cell	surface	receptors	are	broad	and	include:	peptide	
hormones,	 neurotransmitters,	 cytokines,	 adhesion	molecules	 and	 growth	 factors.	 The	 role	 of	 cell	
surface	 receptors	 is	 to	 then	 transduce	signals	 into	cells	 from	the	extracellular	environment,	which	







with	 an	 extracellular	 domain	 comprised	 of	 the	 N-terminus	 flowing	 into	 seven	 hydrophobic	
	
	 21	
transmembrane	domains	connected	by	 three	protruding	extracellular	 loops	and	three	 intracellular	

























































to	 be	 activated,	 (although	 this	 can	 happen	 constitutively	 (Zhang	 et	 al.	 2014))	 it	 is	 predominately	
achieved	through	binding	ligands	that	act	as	agonists.	There	are	a	huge	variety	of	possible	agonists	



























































Gas/olf	 Gai/o	 Gaq/11	 Ga12/13	
as	 ai1,	ai2,	ai3	 aq	 a12	
asXL	 ao	 a11	 a13	
aolf	 at	 a14	 	
	 az	 a15/16	 	
	 agust	 	 	
	
There	 are	multiple	 effectors	 regulated	 by	G	 proteins	 These	 can	 include	 adenylyl	 cyclase	 (AC),	
guanylyl	cyclase	(GC),	phosphodiesterases	(PDEs),	phospholipase	A2	(PLA2),	phospholipase	C	(PLC),	
phosphoinosite	 3-kinases	 (PI3Ks).	 These	 are	 capable	 of	 directly	 or	 indirectly	modulating	 levels	 of	
second	 messengers	 such	 as	 cyclic	 adenosine	 monophosphate	 (cAMP),	 cyclic	 guanosine	
monophosphate	(cGMP),	diacylglycerol	(DAG),	inositol	trisphosphate	(IP3),	phosphatidylinositol	4,5-
bisphosphate	 (PIP2),	 Phosphatidylinositol	 (3,4,5)-trisphosphate	 (PIP3),	 and	 calcium.	G	 proteins	 also	





























(Mizuno	 and	 Itoh	 2009).	 They	 are	 activated	 in	 the	 same	manner	 as	 the	 previous	 G	 proteins,	 but	
activate	a	unique	signalling	cascade:	Gaq/11	binds	and	activates	phospholipase	C	(PLC)	at	the	plasma	


















their	 state	 of	 activation.	 They	 can	 then	 lead	 to	 the	 regulation	 of	 many	 processes	 such	 as	 gene	
expression	and	actin	cytoskeleton	rearrangement	(Sit	and	Manser	2011).	Ga12	and	Ga13	themselves	




in	 the	 example	 of	 the	 parathyroid	 receptor	 (PTHR)	 there	 is	 short	 and	 long	 term	 signalling,	which	
appears	physiologically	relevant	as	short	term	signalling	appears	to	cause	rapid	calcium	mobilisation	
at	the	bone	surface	whereas	long	term	signalling	seems	to	lead	to	bone	growth	(Hanyu	et	al.	2012).	
There	 is	also	evidence	 that	 sustained	 	b-	 adrenenoreceptor	 signalling	 leads	 to	upregulation	of	 the	
PCK1	 gene	 (Tsvetanova	 and	 von	 Zastrow	 2014).	 In	 the	 canonical	 model	 of	 GPCR	 signalling	 these	
second	messengers	 then	 lead	 to	 kinase	 activation	 (GRKs,	 PKA,	 PKC)	 and	negative	 feedback	 to	 the	









two	 non-visual	 arrestins	 in	 humans:	 b-arrestin1	 and	 b-arrestin2.	 Interestingly,	 they	 also	 act	 as	
scaffolds	 for	 G	 protein	 independent	 signalling,	 primarily	 for	 the	 activation	 of	 mitogen-activated	

































Figure	 1.1.	 Typical	 signal	 transduction	 pathways	 downstream	 of	 a	 GPCR	 Schematic	
representation	of	 a	 ligand	 stimulating	 GPCR	 activation;	 capable	 of	 recruiting	 Ga,	 Gq,	 and	b-
arrestin	and	their	subsequent	second	messenger	signaling	pathways	represented	here	by	cAMP,	


















component	 of	 this	 process	 is	 the	 activity	 of	 the	 regulators	 of	 G	 protein	 signalling	 (RGS)	 proteins	
mentioned	above,	the	shorten	the	length	of	time	that	GTP	is	bound	to	a	G	protein	(and	therefore	how	
long	it	is	activated)	through	stimulating	GTP	hydrolysis.	There	are	over	20	members	of	the	RGS	protein	
family	 (Coleman	 et	 al.	 1994).	 Although	 this	 termination	 pathway	 can	 proceed	 as	 above	 for	 some	
receptors,	the	picture	is	much	more	complex	than	the	original	model	for	others;	with	some	receptors	
having	been	shown	to	bind	G	proteins	and	b-arrestins	at	the	same	time	and	forming	a	‘super-complex’	
(Thomsen	et	al.	 2016);	 this	 can	be	attributed	 to	 the	 recently	observed	biphasic	engagement	of	b-
arrestins	by	 receptors	 (Shukla	et	al.	2014)	where	 it	was	 shown	 that	 the	N-terminal	domain	of	 the	
arrestin	 interacts	with	the	phosphorylated	C-terminal	 tail	of	 the	GPCR	first.	Then	a	second	weaker	
interaction	is	possible	which	involves	the	finger	loop	of	the	arrestin	inserting	into	the	receptor	core.	
This	 interaction	 is	 thought	 to	 occlude	 G	 protein	 binding.	 This	 provides	 a	 possible	 explanation	 for	
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ability	 to	 bind	 a	 receptor	 and	 the	 latter	 describes	 their	 ability	 to	 elicit	 a	 functional	 consequence.	
Antagonists	for	example	possess	an	affinity	for	a	receptor	but	no	efficacy,	whereas	agonists	possess	
both,	and	it	is	now	known	both	affinities	and	their	efficacies	can	vary	at	a	single	GPCR	(Wisler	et	al.	
2014).	 Importantly,	bias	 is	a	 relative	 term,	and	 is	usually	 in	 reference	to	a	 ‘balanced	 ligand’	at	 the	
signalling	pathways	or	a	 single	endogenous	agonist	 for	 the	 receptor	 in	 studies	of	 synthetic	biased	
agonists	(Smith	et	al.	2018).	If	we	take	the	ligand	from	(Figure	1.1)	as	an	example	of	a	balanced	ligand	








can	 be	 different	 receptors	 in	 the	 same	 family,	 or	 a	 receptor	 containing	mutations	 that	 means	 it	
recruits	certain	effectors	less	well	(Kliewer	et	al.	2019).	Then	there	is	system	bias	where,	expression	
or	 overexpression	 of	 certain	 proteins	 such	 as	 GRKs,	 G	 proteins	 or	 	b-arrestins	 can	 bias	 a	 system	
towards	a	certain	response,	demonstrating	that	some	bias	can	be	tissue	specific.	 It	 is	 important	to	
Figure	1.2.	Representation	of	GPCR	signalling	bias.	Schematic	representation	of	a	ligand	stimulating	
GPCR	 activation;	 capable	 of	 recruiting	 Ga,	 Gq,	 and	 b-arrestin	 and	 their	 subsequent	 signaling	
pathways	 represented	 here	 by	 cAMP,	 calcium,	 and	 pERK1/2	 respectively.	 	 GPCR	 activation	 and	




























































































































Biased	 agonism	 created	 renewed	 interest	 in	 GPCRs	 as	 therapeutic	 targets,	 by	 providing	 a	way	 to	











drug	 showed	equivalent	 levels	of	 analgesia	with	 reduced	 side	effects	 (Singla	et	 al.	 2019),	 crucially	
when	examined	 specifically	 there	was	 a	 reduction	 in	negative	 respiratory	 side	effects	 (Ayad	et	 al.	
2020)		However,	the	development	of	biased	agonists	is	not	without	its	challenges	and	controversies;	
a	recent	study	of	another	G	protein	biased	agonist	in	mice	still	demonstrated	respiratory	depression	
despite	 being	 G	 protein	 biased	 (Hill	 et	 al.	 2018).	 Furthermore,	 a	 recent	 study	 using	 b-arrestin	
recruitment	deficient	mutations	of	the	µ-opioid	receptor	in	mice	showed	increased	analgesia	but	no	
reduction	in	respiratory	side	effects	(Kliewer	et	al.	2019).	Although	this	does	not	entirely	refute	the	





and	 respiratory	 depression	 (Kliewer	 et	 al.	 2020)	 suggesting	 all	 negative	 side	 effects	 cannot	 be	
attributed	to	b-arrestins.	Overall	this	seems	to	suggest	that	signalling	bias	observed	in	recombinant	
and	mouse	studies	and	how	they	reflect	the	outcomes	seen	in	humans	is	not	as	fully	understood	as	
































the	 interaction	 of	 RAMPs	with	 Family	 B	GPCRs	 as	 such	 at	 least	 9	 of	 the	 18	 Family	 B	GPCRs	 have	





heavily	 studied	 receptor-RAMP	 interaction	 in	 heterologous	 systems,	 and	 the	 RAMPs	 form	 three	
individual	 receptors	 in	 combination	 with	 the	 CLR:	 CLR-RAMP1	 named	 the	 ‘CGRP	 Receptor’,	 CLR-
RAMP2	the	‘AM1	Receptor’	and	CLR-RAMP3	the	‘AM2	Receptor’	(McLatchie	et	al.	1998).	Of	the	three	
the	CLR-RAMP1	 is	 the	only	one	 to	have	had	 its	 structure	 resolved	 (Liang	et	 al.	 2018)	 (Figure	1.3),	














(Zaidi	et	al.	1990,	Alevizaki	et	al.	1986).	When	CGRP	is	discussed	in	the	literature,	and	here,	 it	 is	 in	
reference	to	the	major	a-form	unless	otherwise	stated.	CGRP	is	predominantly	known	physiologically	













any	 physiological	 relevance	 (Gingell	 et	 al.	 2019).	 Research	 has	 also	 suggested	 that	 receptor	
component	 protein	 (RCP)	 is	 essential	 to	 CLR-RAMP	 function	 (Evans	 et	 al.	 2000),	 but	 there	 is	
controversy	over	how	universal	this	protein’s	function	is,	as	it	is	also	a	component	of	RNA	polymerase	
III	 (Hu	 et	 al.	 2002).	 It	 is	 also	 important	 to	 note	 that	 CLR-RAMP2	 and	 CLR-RAMP3,	while	 generally	
considered	as	AM	receptors	also	bind	and	respond	to	CGRP	(Weston	et	al.	2016,	Qi	et	al.	2013)	in	co-
expression	models	but	again	the	relevance	of	this	is	yet	to	be	fully	explored.	As	for	the	pharmacology	




alluded	 to	 above,	 at	 other	 members	 of	 the	 receptor	 family	 with	 the	 rank	 order	 of	 potencies:	
CGRP>AMY1>AMY3>AMY2>CTR>AM2>AM1.	 It	has	also	been	demonstrated	 that	GCRP	can	couple	 to	
Gq/11	and	elicit	calcium	mobilisation	with	a	potency	of	8.19	in	a	HEK-293	cell	line	(Weston	et	al.	2016).	







well	 as	 protecting	 cells	 from	 oxidative	 stress	 via	 ERK/12	 and	 p38	 MAPKs	 (Schaeffer	 et	 al.	 2003),	
although	it	remains	uncertain	which	receptor	CGRP	acted	through.	Then	there	is	the	topic	of	bias,	and	
CGRP	provides	a	good	example	with	the	above	work	suggesting	that	CGRP	at	the	CGRP	receptor	is	
















levels	change	 in	physiological	and	pathophysiological	 conditions;	 firstly,	 in	pregnancy	where	 it	 is	a	
proposed	 vascular	 regulator	 (Dong	 et	 al.	 2002).	 As	 well	 as	 in	 the	 cardiovascular	 disease	 and	
hypertension;	in	these	scenarios	whether	it	has	a	contributory	or	protective	role	is	still	a	source	of	
confusion,	although	it	 is	proposed	to	play	a	protective	role	in	heart	failure	(Brain	and	Grant	2004).	




2004)	 and	 then	 with	 monoclonal	 antibodies,	 the	 first	 of	 which	 to	 be	 approved	 was	 Erenumab	
(Goadsby	et	al.	2017).	Even	more	recently	small	molecule	positive	modulators	have	been	identified	
for	the	CLR	including	the	CGRP	receptor	with	great	therapeutic	potential	(Hendrikse	et	al.	2020).		
Systemic	 administration	 of	 CGRP	 in	 healthy	 human	 causes	 vasodilation	 (Gennari	 and	 Fischer	
1985),	what	is	more	in	the	microvasculature	it	is	the	most	potent	vasodilator	known	(Brain	et	al.	1985).	

























It	 is	 thought	 that	CGRP	mediates	 its	vasodilatory	effects	 through	a	combination	of	effects	and	
pathways	in	endothelial	and	smooth	muscle	cells	(SMCs)	but	that	endothelial	cells	are	not	essential	
as	vasodilation	can	be	observed	 in	SMCs	without	endothelial	 cells	present	 in	a	 study	using	bovine	
derived	cells	(Crossman	et	al.	1990).	Although	there	is	the	caveat	that	the	evidence	presented	for	this	






hydrochloride	 (L-NAME)	 based	 inhibition	 of	 NO	 production	 also	 inhibited	 cGMP	 production	 and	
relaxation	 (Gray	 and	 Marshall	 1992).	 It	 was	 also	 concluded	 that	 cAMP	 increases	 caused	 NO	
production,	 although	 there	 was	 no	 evidence	 linking	 the	 two.	 This	 suggests	 that	 the	 picture	 is	
incomplete	and	further	work	is	needed	to	elucidate	the	signalling	mechanisms	for	vasodilation,	and	



















although	 it	 seems	 to	be	of	 limited	physiological	 significance	as	 truncation	of	 it	 has	 little	 effect	on	













RAMP1)	 receptor.	 This	 is	 based	 on	 the	 study	 combining	multiple	 co-expression	 studies	 using	 the	
human	receptor.	The	rank	order	of	pEC50	values	is	AM2	(9.36)>AM1(9.19)>CGRP(8.09)	(Hay	et	al.	2018),	
suggesting	AM	is	not	actually	most	potent	at	the	receptor	that	takes	its	name	but	that	it	 is	slightly	




weak	 cAMP	 response	 (Gs).	 However,	 it	 has	 been	 shown	 that	 AM	 in	 fact	 also	 signals	 through	 Gi/o	
proteins	at	 the	CGRP	receptor.	Providing	an	explanation	for	 the	weak	cAMP	signal	 induced.	 In	 the	
same	publication,	 there	was	also	evidence	of	AM	evoking	Gq/11	coupling	 to	 the	CLR	 (Weston	et	al.	
2016).	 Thus	 far	 these	 results	 have	 only	 been	 shown	 in	 overexpression	 systems	 and	 need	
demonstrating	 in	 the	 native	 system	 in	 order	 to	 determine	 the	 physiological	 relevance	 of	 AM	and	
AM2’s	biased	signalling.		
In	 terms	 of	 internalisation	 and	 receptor	 recycling,	 research	 suggests	 AM	 can	 drive	 the	
internalisation	of	CGRP,	AM1,	and	AM2	receptors	(Nikitenko	et	al.	2006).	Furthermore,	it	is	likely	to	












AM	 is	 widely	 expressed	 in	 the	 human	 body;	 systems	 of	 note	 where	 it	 is	 found	 are	 the	
cardiovascular,	 placenta,	 reproductive	 and	 blood	 (Eto	 et	 al.	 2003,	 Ichiki	 et	 al.	 1994).	 Although	




In	terms	of	AM’s	physiology	AM	is	 involved	in	 lymphangiogenesis	and	the	control	of	 lymphatic	








et	 al.	 1994)	however,	 it	 is	 not	 clear	whether	 it	 is	 via	 a	 cAMP-dependent	or	 -independent	method	
(Tsuruda	et	al.	2019).	 It	 is	thought	AM	plays	multiple	roles	 in	endothelial	cells,	another	of	which	is	
regulating	 endothelial	 barrier	 function	 (Temmesfeld-Wollbrück	 et	 al.	 2007).	 It	 is	 thought	 to	 cause	
barrier	 stabilisation	 and	 protect	 against	 infection	 mediated	 junctional	 protein	 disappearance.	 All	
brought	 about	 initially	 through	 cAMP	 production	 (Hocke	 et	 al.	 2006).	 In	 the	 heart,	 and	 cardiac	
myocytes,	AM	is	also	synthesised,	however	its	exact	role	is	a	source	of	much	controversy	(Bisping	et	
al.	2007).	Some	report	that	AM	is	a	positive	inotrope	acting	in	the	same	cAMP	driven	manner	as	b-




widely	 acknowledged	 to	 be	 cardioprotective	 through	 regulating	 cell	 proliferation	 as	 it	 has	 an	
antiapoptotic	effect	on	endothelial	cells,	reportedly	in	a	cAMP-independent	manner	via	NO	(Sata	et	
al.	 2000).	 AM	 can	 also	 increase	 cardiac	 output	 by	 causing	 vasodilation	 of	 coronary	 vessels	 and	
decreasing	 vascular	 resistance	 (Nagaya	 et	 al.	 2000).	 The	 potent	 vasodilatory	 effects	 of	 AM	 are	
important	in	the	lung	circulation	and	can	decrease	vascular	resistance	in	pulmonary	hypertension	as	











first	 discovered	 in	 2004	 (Roh	 et	 al.	 2004,	 Takei	 et	 al.	 2004)	 and	 is	 the	 final	member	 of	 the	 CGRP	
superfamily	of	peptides	to	be	addressed	in	detail	here,	as	well	as	the	least	well	understood	(Hay	et	al.	
2018).	This	peptide	hormone	is	again,	as	with	the	others,	an	agonists	at,	and	exerts	its	physiological	
effects	 through,	 the	 CLR	 (Hay	 et	 al.	 2005).	 Physiologically,	 AM2	 has	 effects	 on	 the	 cardiovascular	
system,	adipose	 tissue,	macrophages	and	 the	kidney,	 it	 can	also	activate	 the	sympathetic	nervous	
system	 (Hong	 et	 al.	 2012).	 AM2	 is	 a	 53	 amino	 acid	 peptide.	 The	 human	 AM2	 gene	 is	 found	 on	
chromosome	22	and	codes	for	prepro-AM2	which	 is	148	amino	acid	residues	 in	 length	before	 it	 is	




AM21-40	 (Morimoto	 et	 al.	 2007).	 Currently	 antibodies	 cannot	 distinguish	 between	 them	 and	 the	
prominence	 of	 each	 in	 vivo	 remains	 uncertain.	 As	 does	 the	 physiological	 and	 pharmacological	
relevance	of	these	cleavage	fragments.	AM2	shares	the	conserved	residues	with	the	other	members	







of	 multiple	 co-expression	 studies	 using	 the	 human	 receptor	 the	 rank	 order	 of	 potencies	 at	 each	















































While	 specific	 aims	will	 be	 outlined	 subsequently	 in	 individual	 chapters	 there	 are	 some	 clear	
overarching	aims	of	this	body	of	work.	The	first	is	to	explore	the	extent	of	CLR	signalling	bias	where	it	
is	endogenously	expressed.	Much	work	as	outlined	above	has	profiled	the	signalling	of	this	receptor	
using	overexpression	 in	 immortalised	cell	 lines.	This	work	aims	 to	explore	 the	signalling	 in	a	more	
physiologically	 relevant	 system.	 Then	 a	 further	 aim	 will	 be	 to	 assess	 how	 RAMPs	 influence	 this	





be	 explored	 whether	 there	 are	 spatiotemporal	 aspects	 to	 the	 signalling	 of	 the	 receptors	 in	 the	
endogenous	 setting	 and	 whether	 this	 can	 be	 observed,	 as	 well	 as	 seeing	 whether	 different	
endogenous	ligands	evoke	different	spatiotemporal	responses	in	the	same	receptor	and	cell	system.	
Then	 finally	gene	editing	 techniques	will	be	used	to	 interrogate	whether	 the	contrasting	signalling	
responses	from	the	CLR	ligands,	seen	in	different	primary	cell	lines	is	related	to	the	differing	RAMP	









(22-52)	 (all	 Bachem	UK	 Ltd,	 St.	 Helens,	 UK)	 are	 dissolved	 in	water	 containing	 0.1%	Bovine	 Serum	
Albumin	 (BSA),	 to	 a	 1	 mM	 concentration	 and	 stored	 as	 7	 μl	 aliquots.	 VEGF,	 acetylcholine	 and	





Aldrich),	 Rp-8-Br-cAMPs	 (Santa	 Cruz	 Biotechnology)	 are	 dissolved	 in	 DMSO	 at	 10	 mM.	 PTX	 was	
purchased	 in	 solution	 (ThermoFisher	 Scientific,	 Waltham,	 MA,	 USA).	 Barbadin	 (Aobious,	





















































































incubator	 (37	 °C,	 humidified	95%	air,	 5%	CO2)	 between	passaging.	 Primary	 cell	 lines;	HUVECs	 and	





























































0.1vol	 (5	 μl)	 10X	DNase	 1	 buffer	 is	 added	 (30	min,	 37°C)	 to	 remove	possible	 contamination	 from	
genomic	DNA.	Finally,	DNase	inactivation	reagent	0.1vol	(5.6	μl)	is	added	(1	min,	RT)	then	the	solution	
is	 spun	 (10,000	 rpm,	 30	 secs)	 and	 supernatant	 collected.	 Purity	 of	 RNA	 samples	 quantified	 using	
NanoDrop	Lite	spectrophotometer	(Thermo	Scientific),	samples	with	yields	over	100	ng/μl	and	with	
A260/280	vaules	over	1.9	used.	








Electrophoresis	 is	performed	on	a	2%	agarose	 (in	TAE)	gel.	The	 Image	 is	captured	using	G	Box	
iChemi	 gel	 documentation	 system	 utilising	 GeneTools	 analysis	 software	 (Syngene)	 densitometry	










(100	 µM,	 15	 min)(Almahariq	 et	 al.	 2013).	 Rp-8-Br-cAMPs	 the	 PKA	 inhibitor	 has	 pre-treatment	
conditions	of	(100	µM,	15	min)	(Schwede	et	al.	2000).	PTX	inactivates	Gai	proteins	and	requires	(200	
ng/ml,	16	h,	37	°C)	pre-treatment	conditions	(Weston	et	al.	2016).	The	GPCR	internalisation	inhibitors	
have	 the	 following	 pre-treatment	 conditions:	 Barbadin	 (100	µM,	 30	min)	 (Beautrait	 et	 al.	 2017),	




























each	 well,	 the	 cells	 are	 thoroughly	 dislodged	 through	 repeated	 pipetting,	 and	 added	 to	 1.5	 μl	
Eppendorf	 tubes.	 The	 cells	 are	 centrifuged	 (1000rpm,	 5	min)	 to	 form	 a	 pellet	 so	 than	 the	 trypsin	
containing	 media	 can	 be	 removed.	 The	 cells	 are	 washed	 and	 re-suspended	 in	 500	 μl	 PBS	 and	
centrifuged	two	further	times	before	final	resuspension	in	PBS.	A	10	μl	aliquot	of	each	cell	suspension	
is	 added	 to	a	haemocytometer.	 It	 is	used	 to	 count	 the	number	of	 cells	 in	a	given	area,	under	 the	
microscope,	to	calculate	the	number	of	cells/μl.	This	process	is	also	carried	out	for	pERK1/2	assays.	




















After	 the	 30	min	 incubation	 period	 10	 μl	 of	 detection	 buffer	 is	 added	 to	 all	 wells	 before	 the	
Optiplate	 is	 again	 covered	 in	 foil	 and	 incubated	on	 the	 shaker	plate	 (room	 temperature,	 60	min).	
Following	the	incubation	period,	the	Optiplate	is	immediately	read	by	the	Mithras	LB	940	multimode	
microplate	reader	(Berthold	technologies,	Harpenden,	UK).	Light	pulses	from	the	plate	reader	at	340	




































































cAMP	 accumulation	 assay	 section.	 Ligands	 are	 also	 diluted	 in	 HBSS-BSA	 (as	 in	 above	 assays	 and	
described	in	detail	in	cAMP	assay	section).	Cells	are	then	plated	on	384	well	plates	in	8	μl	aliquots	at	
a	density	of	35,000	cells/well.	Next	Ligands	are	added	(4	μl)	for	5	min	stimulation	at	room	temperature	
in	 this	 range	10-4	M	to	10-11	M,	 ligands	are	diluted	as	described	above.	Cells	are	 then	 lysed	as	per	
manufacturer’s	instructions	with	4μl	of	lysis	buffer	(Cisbio	phosphor-ERK1/2	cellular	assay	kit)	for	30	









All	 cell	 lines	 were	 cultured	 and	 trypsinised	 as	 above	 in	 order	 to	 be	 seeded	 at	 a	 density	 of	
2500	cells/well	 in	a	clear	flat	bottom	96-well	plate	(Corning,	NY,	USA)	and	incubated	at	37°C	in	5%	
CO2.	 After	 24	 h,	 cells	 were	 exposed	 to	 ligands	 and	 control:	 the	 dilution	 series	 is	 performed	 as	
explained	 in	 extensive	 detail	 above	 but	 in	 complete	 endothelial	 cell	 growth	 media	 (HUVECs	 and	
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produce	 concentration-response	 curves	 for	 agonist	 stimulation.	 Where	 he	 means	 of	 individual	
experiments	were	combined	to	generate	the	curves	shown.	 In	the	case	of	calcium	and	nitric	oxide	
(time	resolved)	assays	images	are	stacked,	corrected	for	background	fluorescence	and	peak	intensity	





data	 generated	 in	 the	 ERK1/2	 assay	 the	 fluorescence	 reading	 at	 665	 nm	 is	 divided	 by	 the	 620	 nm	
reading	 and	 the	 result	multiplied	 by	 1000	 for	 every	 individual	well.	 The	 resulting	 data	were	 then	
further	 analysed	 in	 GraphPad	 Prism	 8.4,	 where	 values	 are	 normalised	 to	 ERK1/2	 phosphorylation	
caused	from	cells	 in	response	to	100	μM	phorbol	12-myristate	13-acetate	(PMA).	Cell	proliferation	
was	 calculated	as	a	percentage	of	number	of	 cells	 treated	with	vehicle	alone.	Data	were	 fitted	 to	
obtain	concentration–response	curves	using	either	the	three-parameter	 logistic	equation	-	used	to	
obtain	 values	 of	 Emax	 and	 pEC50	 or	 the	 operational	 model	 of	 receptor	 agonism	 was	 used	 where	








ratios	of	each	pathway	 to	one	another	on	a	 logarithmic	 scale.	Correlations	between	pEC50	values	














use	and	 thawed	according	 to	 the	manufacturer’s	 instructions	as	outlined	above	 in	 the	cell	 culture	
section.	Wells	to	be	used	of	an	E-Plate	CardioECR	48	(ACEA	Biosciences,	Inc.	San	Diego,	CA,	USA)	are	
coated	in	gelatine	(50	µl,	0.1%)	(Sigma-Aldrich)	2	hours	before	plating.	Thawed	cells	are	diluted	in	pre-
warmed	 iCell	 CM	plating	medium	and	 then	plated	 at	 30,000	plateable	 cells/well	 in	 100	µl	 plating	
media.	Cells	were	allowed	to	adhere	at	room	temperature	for	15	min.	Then	placed	in	a	humidified	
incubator	with	5%	CO2	at	37°C.	Plating	media	is	replaced	with	iCell	cardiomyocyte	maintenance	48	h	




iCell	 Cardiomyocytes	 (Cellular	 Dynamics,	 Madison,	 WI,	 USA)	 were	 thawed	 according	 to	 the	














position	 exactly	 above	 the	 central	 sensing	 electrode	 located	 in	 the	 well	 base	 when	 they	 are	
transferred:	Spheroids	are	 transferred	using	a	multi-channel	manual	pipettor	equipped	with	wide-





















addition;	 ensuring	 200	 µl/well	 volumes.	 This	 becomes	 250	 µl	 with	 ligand/control	 addition	 (50	 µl	
compound	added	in	Maintenance	media).	Immediately	after	ligand/control	addition	Sensor	plates	are	
loaded	onto	 a	CardioEcyte96	platform	 (Nanion	Technologies)	 (Doerr	 et	 al.	 2015).	 Impedance	data	
were	 then	 collected	with	 reading	 sweeps	 taken	 every	minute.	 Data	were	 then	 exported	 to	 Prism	

















Media	 is	 then	 removed	and	cells	are	washed	 in	PBS.	RNA	 is	extracted	and	gDNA	eliminated	using	
QIAGEN	 RNA	 extraction	 kit	 as	 per	manufacturer’s	 instructions.	 The	 yield	 and	 quality	 of	 RNA	was	
assessed	 by	 measuring	 absorbance	 at	 260	 and	 280	 nm	 (Nanodrop	 ND-1000	 Spectrophotometer,	
NanoDrop	 technologies	 LLC).	 RNA	 was	 used	 immediately	 for	 the	 preparation	 of	 cDNA	 using	 the	
Multiscribe	reverse	transcriptase.	For	the	preparation	of	cDNA	100	ng	of	RNA	was	reverse	transcribed	




assays	 according	 to	 manufacturer’s	 instructions	 (Life	 Technologies,	 MA,	 USA)	 for	 GAPDH	
(Hs02786624_g1),	CALCR	(Hs01016882_m1),	CALCRL	(Hs00907738_m1),	RAMP1	(Hs00195288_m1),	
RAMP2	 (Hs01006937_g1),	 RAMP3	 (Hs00389131_m1)	 and	 plated	 onto	 fast	 microAmp	 plates	




























RAMP2	 protein	 (Discovery	 Antibodies)	 (diluted	 at	 various	 manufacturer	 recommended	
concentrations	 in	 PBS/0.05%	 Tween/3%	 BSA)	 at	 4°C,	 overnight	 and	 protected	 from	 light	 (other	
primary	antibodies	described	in	the	sections	they	were	used).	The	cells	were	washed	three	times	with	
PBS	 and	 incubated	 with	 AlexaFluor	 488	 donkey	 anti-rabbit	 /	 AlexaFluor	 568	 goat	 anti-rabbit	
(Invitrogen,	1/500)	(1hr,	RT)	protected	from	light.	Cells	were	washed	three	times	with	PBS,	then	nuclei	



















HUVECs	 with	 the	 RAMP2	 gene	 knocked	 out	 or	 the	 control	 HPRT1	 gene	 knocked	 out	 were	
generated	by	CRISPR/Cas9	homology	directed	repair	(Ran	et	al.	2013).	The	sgRNA	sequences	that	were	
designed	 and	 manufactured	 targeting	 RAMP2	 were	 (5’-CGCTCCGGGTGGAGCGCGCCGG-3’),	 (5’-




An	 optimal	MOI	 of	 transduction	 had	 to	 be	 established	 to	 do	 this	 -	 cells	 at	 90%	 confluency	were	
harvested	from	flasks	with	Trypsin,	then	plated	in	cell	carrier	ultra	96	well	plate	at	10,000	cells	per	
well	 and	 incubated	 24	 hours,	 37°C	 5%	 CO2.	 Such	 that	 24	 h	 later	 cells	 were	 approximately	 70%	













diluted	1/700	 in	PBS/0.05%	Tween/3%	BSA)	 at	 4°C,	 overnight	 and	protected	 from	 light.	 	 Cells	 are	
washed	 three	 times	 in	PBS	and	 then	 incubated	 in	1:2000	dilution	of	Hoechst	 (Invitrogen)	 in	PBS	+	
0.05%	Tween20	+	3%	BSA	for	1	hour	protected	from	light.	The	cells	were	stored	at	4°C	prior	to	imaging	
to	imaging	on	CV7000	as	outlined	previously.		















Sequencing	 of	 genomic	 loci	 was	 performed	 by	 first	 extracting	 Genomic	 DNA	 from	 virally	
transduced	HUVEC	cells	by:	collecting	approximately	10,000	cells,	washing	in	PBS	(sigma-Aldrich)	and	
then	 lysing	with	DirectPCR	 Lysis	 Reagent	 (Viagen	Biotech)	 containing	Proteinase	K	 (Qiagen)	 at	 0.4	
mg/ml.	The	lysate	was	incubated	at	55°C	for	4	h;	85°C,	for	10	min;	12°C	for	12	h.	PCR	reaction	was	
then	set	up	in	(20	μl)	as	follows:	2x	Flash	Phusion	PCR	Master	Mix	(Thermo	Fisher)	(20	μl),	forward	


















































































the	 unique	 requirement	 of	 CLR	 to	 dimerise	 with	 a	 RAMP	 in	 order	 to	 traffic	 and	 function	 it	 was	
imperative	 that	 a	 cell	 line	was	 identified	 that	only	 expressed	a	 single	 	 RAMP:	 (RAMP1,	RAMP2	or	
RAMP3).	To	enable	the	receptor	activity	observed	to	be	purely	attributed	to	one	CLR-RAMP	complex,	
and	 thus	 further	our	understanding	of	 that	complex,	 rather	 than	 there	being	question	marks	over	
where	the	signalling	comes	from.	Further	to	this	 it	was	also	 important	to	 identify	a	cell	model	not	
expressing	CTR,	as	the	only	other	receptor	known	to	bind	and	respond	to	the	CGRP	family	peptides.	
In	the	literature	HUVECs	have	been	used	for	a	long	time	as	a	good	primary	model	for	endothelial	cell	
function	 at	 early	 passage	 numbers	 (Jaffe	 et	 al.	 1973,	 Onat	 et	 al.	 2011),	 and	 having	 recorded	




question.	 	Following	successful	 identification	of	the	CLR	in	this	cell	 line	the	aim	was	to	identify	the	
expression	of	proteins	relevant	to	GPCR	signalling.	As	well	as	establish	the	primary	cell	model	 in	a	
variety	 of	 intracellular	 signalling	 assays	 and	 profile	 the	 signalling	 responses	 that	 the	 endogenous	
peptides	could	elicit	through	the	CLR.	Depending	on	the	RAMP	present	it	was	established	whether	the	








are	overexpressed	 in	these	cells	 (Hay	et	al.	2018).	However,	 the	background	expression	 in	them	is	
often	overlooked/left	unexplored	(Weston	et	al.	2016).	Moreover,	even	when	the	cell	line	in	question	




HEK-293	 cells	 with	 a	 ‘clean	 background’.	 These	 results	 here	 could	 then	 be	 viewed	 in	 light	 of	 the	
pharmacological	studies	performed	in	the	primary	cell	system.	
Then	 returning	 to	primary	cells	 and	having	established	HUVECs	as	a	good	and	novel	model	of	
endogenous	CLR/RAMP2	function	the	aim	was	to	identify	another	primary	cell	 line	expressing	only	




was	 to	 find	a	primary	 cell	 line	expressing	CLR/RAMP1,	 to	establish	how	 the	CGRP	 family	peptides	










	RT-PCR	was	 performed	 in	 HUVECs	 using	 oligonucleotides	 for	 the	 CLR-related	 components	 of	
interest.	 This	was	 done	 alongside	 a	 housekeeping	 gene	 (GAPDH)	 for	 reference	 and	 normalisation	








Figure	 3.1.	 	 Calcitonin	 family	 Receptor	
expression	 in	 HUVECs.	mRNA	Expression	of	
CALCR,	CALCRL,	RAMP1,	RAMP2,	and	RAMP3	
genes	 in	 HUVECs	 as	 determined	by	 RT-PCR.	
Data	 represent	 mean	 +	 S.E.M.	 of	 3	
independent	experiments	relative	to	GAPDH	
























































µM)	 using	multiple	 passages	 (between	 P1	 and	 P6)	 (Figure	 3.2).	 This	 shows	 that	 there	 is	 a	 dose-
dependent	relationship	between	the	concentration	of	forskolin	added	and	the	concentration	of	cAMP	
measured.	 These	data	 confirm	 that	 these	 cells	 had	 all	 the	 apparatus	 necessary	 to	measure	 cAMP	
accumulation	 in	 response	 to	 ligand	 stimulation.	 Therefore,	 it	 could	 be	 seen	whether	 there	was	 a	
detectable	cAMP	response	when	a	GPCR	shown	to	be	present	at	the	mRNA	level	(CLR)	was	stimulated	
with	ligands	known	to	activate	it	(CGRP,	AM	and	AM2).		
Figure	 3.2:	 cAMP	 Production	 in	
HUVECs.	 Characterisation	 of	 cAMP	
accumulation	 in	 response	 to	
stimulation	 by	 forskolin	 over	 a	
concentration	 range	 of	 100	 pM	 to	
100µM.	 Data	 are	 analysed	 using	 a	
three-parameter	 non-linear	
regression	curve.	All	values	represent	
mean	 +	 S.E.M.	 calculated	 from	 4	
Independent	experiments. 













































































































































	   cAMP	 	  
		 CGRP	 AM	 AM2	
pEC50	 5.46****	 0.39	 7.95	 0.07	 7.24	 0.11	
Emax	 27.14*	 6.75	 45.17	 1.17	 32.75	 1.21	
pKa	 5.61****	 0.25	 7.67	 0.09	 6.99****	 0.14	
logt	 -0.51***	 0.09	 -0.10	 0.02	 -0.33	 0.03	






The	 next	 signalling	 pathway	 downstream	 of	 GPCRs	 to	 consider	 in	 exploring	 and	 profiling	 the	
signalling	of	this	peptide	family	in	HUVECs	is	ERK1/2	phosphorylation.	First	a	commonly	used	positive	
control	was	established:	PMA	(Verin	et	al.	2000)	could	produce	a	measurable	response	in	these	cells	







AM	 (pEC50:	 6.36±0.12)	 and	 over	 100	 times	 more	 potent	 than	 AM2	 (pEC50:	 5.45±0.20).	 Again	



























sets.	pEC50:	negative	 logarithm	of	 the	agonist	concentration	 required	 to	 produce	a	half-
maximal	response.	Emax:	maximal	response	to	ligands	expressed	as	a	percentage	of	PMA.	
pKa:	negative	logarithm	of	the	equilibrium	dissociation	constant	for	each	ligand	generated	
using	 the	 operational	 model	 of	 agonism	 (Black	 and	 Leff	 1983).	 Log!:	 coupling	 efficiency	













HUVEC pERK1/2  activation
PMA











































	 	 	 pERK1/2	 	 	
		 CGRP	 AM	 AM2	
pEC50	 7.71***	 0.10	 6.36	 0.12	 5.45**	 0.20	
Emax	 35.17	 1.13	 30.16	 1.75	 33.30	 4.59	
pKa	 7.46***	 0.10	 6.18	 0.13	 5.41**	 0.19	
logt	 -0.28	 0.02	 -0.38	 0.04	 -0.35	 0.08	








without	 background	 CTR/CLR/RAMP	 expression)	 HEK-293S’s	were	 looked	 at	 to	 see	 if	 there	was	 a	
difference	 in	 background	 expression	 (Figure	 3.5).	 Using	 calcitonin	 and	 CGRP	 there	 was	 a	 clear	
difference;	 in	 the	un-transfected	HEK-293S	cells	 that	had	not	undergone	receptor	KO	both	 ligands	
produced	a	potent	response	(Figure	3.5.A)	whereas	in	the	‘clean	background’	HEK-293S	cells	only	a	
very	small	response	was	observable	above	baseline	at	the	highest	concentration	(Figure	3.5.B).	Then	
the	 CLR	 and	 three	 RAMPs	were	 individually	 over-expressed	 in	 this	 clean	 background	 cell	 line	 and	
profiled	the	signalling	of	CGRP,	AM	and	AM2	through	cAMP	production	and	then	directly	compare	
this	to	the	responses	observed	in	primary	human	cells.	As	well	as	ERK1/2	signalling	to	potentially	inform	
the	 understanding	 of	 the	 primary	 cell	 ERK1/2	 signalling	 (Figure	 3.4).	 The	 rank	 order	 of	 potencies	
produced	 in	 the	 cAMP	 assays	 for	 CLR-RAMP2	 (Figure	 3.6B)	 corresponded	 with	 the	 cAMP	 data	







the	 CLR-RAMP1	 expressing	 cells	 (Figure	 3.6A).	 Here	 it	 was	more	 potent	 at	 pERK1/2	 than	 at	 cAMP	
accumulation.	The	responses	produced	by	CGRP,	AM	and	AM2	were	also	less	distinct	from	each	other	




















































































































































































































































Table	 3.3.	 cAMP	 signalling	 in	 HEK-293	 cells	 co-expressing	CLR-RAMP1,	 CLR-RAMP2	 and	














	  CGRP	 AM	 AM2	
CLR-
RAMP1	
pEC50	 7.62	 0.07	 6.05****	 0.12	 6.84**	 0.07	
Emax	 76.99	 1.77	 79.14	 4.83	 69.48	 1.78	
pKa	 6.98	 0.09	 5.40***	 0.20	 6.35*	 0.08	
Logt	 0.51	 0.04	 0.54	 0.13	 0.32	 0.04	
n	 3	 3	 3	
	        
  CGRP	 AM	 AM2	
CLR-
RAMP2	
pEC50	 6.17**	 0.12	 7.17	 0.11	 6.42**	 0.13	
Emax	 46.24*	 2.65	 58.84	 1.91	 55.31	 3.02	
pKa	 5.93**	 0.14	 6.85	 0.12	 6.11*	 0.15	
Logt	 -0.12	 0.05	 0.03	 0.04	 0.03	 0.06	
n	 3	 3	 3	
	        
  CGRP	 AM	 AM2	
CLR-
RAMP3	
pEC50	 5.22	 0.65	 6.50	 0.19	 6.59	 0.20	
Emax	 41.18	 23.24	 47.84	 3.72	 53.91	 4.23	
pKa	 5.00	 0.82	 6.23	 0.21	 6.29	 0.23	
Logt	 -0.17	 0.42	 -0.07	 0.07	 0.01	 0.08	
n	 3	 3	 3	
	        
  pERK1/2	
	  CGRP	 AM	 AM2	
CLR-
RAMP1	
pEC50	 5.88	 0.35	 6.82	 0.13	 5.74	 0.44	
Emax	 41.21	 8.96	 32.83	 1.70	 41.01	 10.60	
pKa	 5.65	 0.39	 6.65	 0.13	 5.52	 0.50	
Logt	 -0.14	 0.16	 -0.33	 0.04	 -0.19	 0.20	
n	 3	 3	 3	
	        
  CGRP	 AM	 AM2	
CLR-
RAMP2	
pEC50	 5.60	 0.22	 5.56	 0.35	 5.92	 0.24	
Emax	 43.16	 6.04	 32.04	 7.52	 24.81	 3.40	
pKa	 5.36	 0.25	 5.40	 0.39	 5.81	 0.26	
Logt	 -0.14	 0.11	 -0.35	 0.15	 -0.51	 0.08	
n	 3	 3	 3	
	        
  CGRP	 AM	 AM2	
CLR-
RAMP3	
pEC50	 5.06	 0.43	 5.77	 0.31	 5.36	 0.42	
Emax	 32.28	 14.64	 12.25	 1.95	 24.04	 7.11	
pKa	 4.90	 0.53	 5.73	 0.32	 5.26	 0.46	
Logt	 -0.34	 0.30	 -0.95	 0.10	 -0.56	 0.19	









using	 vascular	 smooth	muscle	 cells	 (HVSMCs)	was	explored	as	 a	model	 alongside	profiling	HUVEC	
receptor	expression,	cAMP	and	pERK1/2	responses,	the	same	experiments	were	performed	in	HVSMCs.	
The	cAMP	and	ERK1/2	assays	performed	promisingly	suggested	that	there	was	functional	CLR	at	the	




current	 paucity	 in	 well	 regarded	 antibodies	 (Hay	 et	 al.	 2018)	 (and	 indeed	 later	 optimisation	
experiments	potentially	confirming	this	(Supplemental	Figure	8.10))	meant	that	this	was	not	possible	
at	 the	 time	 to	easily	 assess	with	 certainty	whether	only	RAMP1	was	expressed	at	 the	 cell	 surface	


















genes	 relative	 to	 GAPDH	 in	 HVSMCs.	 Determined	 by	 RT-PCR	 (C).	 Data	 are	 analysed	 using	 a	 three-
parameter	non-linear	regression	curve.	All	values	are	calculated	from	at	least	3	individual	data	sets. 
Table	3.4.	cAMP	signalling	and	ERK	activation	in	HVSMCs.	Characterisation	of	cAMP	accumulation	in	






	   cAMP	 	  
		 CGRP	 AM	 AM2	
pEC50	 7.79	 0.11	 5.97	 0.16	 6.59	 0.11	
Emax	 33.61	 1.21	 33.72	 3.00	 34.37	 1.51	
pKa	 7.60	 0.11	 5.79	 0.15	 6.45	 0.13	
logt	 -0.33	 0.03	 -0.33	 0.05	 -0.32	 0.04	
n	 4	 4	 4	
 
	   pERK1/2	 	  
		 CGRP	 AM	 AM2	
pEC50	 6.27	 0.22	 7.69	 0.29	 5.33	 0.43	
Emax	 18.16	 2.00	 15.28	 1.57	 18.80	 5.38	
pKa	 6.16	 0.25	 7.52	 0.27	 5.56	 0.32	
logt	 -0.70	 0.07	 -0.80	 0.05	 -0.75	 0.11	
n	 3	 3	 3	
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receptor	 at	 the	 cell	 surface.	 However,	 in	 order	 to	 prove	 beyond	 doubt	 that	 all	 cAMP	 responses	
produced	by	the	CGRP	family	of	peptides	were	due	to	CLR-RAMP2	receptor	signalling	attempts	were	
made	to	antagonise	the	response	using	a	known	antagonist	of	the	CLR-RAMP2	receptor	(Hay	et	al.	
2003):	AM22-52.	A	cleaved	version	of	 full	 length	adrenomedullin	peptide	with	no	 intrinsic	agonist	
ability.	 Experiments	 were	 also	 performed	 to	 attempt	 to	 antagonise	 the	 cAMP	 responses	 with	
Olcegepant:	 the	 clinically	 approved	 antagonist	 of	 the	 CLR-RAMP1	 receptor	 (Petersen	 et	 al.	 2005).	




























































































































































































adrenomedullin	 (AM)	 and	 adrenomedullin	 2	 (AM2)	 in	 HUVECs	 in	 the	 presence	 and	
absence	of	100	nM	AM22-52	or	Olcegepant	respectively.	All	relative	to	100	µM	Forskolin.	
Data	 are	 analysed	 using	 a	 three-parameter	 non-linear	 regression	 curve.	 Statistical	
significance	 determined	 compared	 to	 control	 using	 an	 unpaired	 t	 test	 with	 Welch’s	












Table	 3.5.	 Antagonism	 of	 cAMP	 signalling	 in	 HUVECs	 with	 CLR-RAMP2	 and	 CLR-RAMP1	
antagonists.	Characterisation	of	cAMP	accumulation	in	response	to	stimulation	by	CGRP,	AM,	
and	 AM2	 in	 HUVECs	 in	 the	 presence	 and	 absence	 of	 100	 nM	 AM22-52	 or	 Olcegepant	




	   AM22-52	 	  
		 CGRP	 AM	 AM2	
pEC50	 7.08	 1.81	 6.69**	 0.11	 6.67*	 0.24	
Emax	 2.71**	 1.71	 47.68	 2.16	 26.74*	 2.67	
pEC50	(c)	 6.24	 0.28	 8.08	 0.13	 7.52	 0.16	
Emax	(c)	 27.36	 4.60	 45.66	 1.74	 42.02	 2.15	
n	 3	 3	 3	
 
	   Olcegepant	 	  
		 CGRP	 AM	 AM2	
pEC50	 5.70	 0.18	 7.82	 0.12	 7.20	 0.14	
Emax	 38.74	 4.93	 46.90	 1.72	 36.91	 1.82	
pEC50	(c)	 5.79	 0.20	 7.88	 0.15	 7.15	 0.17	
Emax	(c)	 40.54	 4.58	 48.93	 2.43	 34.14	 2.17	














































































































































Figure	 3.9.	 CGRP	 family	 peptide	 cAMP	 signalling	 in	 HUVECs	 beyond	 passage	 6.	






Table	 3.6	 CGRP	 family	 peptide	 cAMP	 signalling	 in	 HUVECs	 beyond	 passage	 6.	
Characterisation	 of	 cAMP	 accumulation	 in	 response	 to	 stimulation	 by	 CGRP,	







Passage pEC50 S.E.M. Emax S.E.M. n
6 5.78 0.12 14.72 3.44 3
7 5.44 0.18 21.80 1.62 3
8 5.87 0.35 24.15 8.06 3
9 6.03 0.25 22.49 2.46 3
10 5.62 0.33 22.50 5.58 3
11 5.79 0.19 26.28 0.61 3
12 5.83 0.42 27.03 1.12 3
13 5.38 0.08 29.24 2.08 3
14 5.62 0.42 21.67 4.17 3
AM
Passage pEC50 S.E.M. Emax S.E.M. n
6 7.91 0.22 44.12 2.00 3
7 7.82 0.24 47.10 1.62 3
8 7.66 0.12 40.52 1.23 3
9 8.13 0.25 40.53 1.24 3
10 8.59 0.28 49.45 3.51 3
11 7.80 0.19 39.50 0.72 3
12 8.16 0.34 50.54 0.95 3
13 7.83 0.13 40.39 2.80 3
14 7.94 0.41 43.29 3.42 3
AM2
Passage pEC50 S.E.M. Emax S.E.M. n
6 6.56 0.16 26.28 1.73 3
7 6.67 0.19 32.12 6.55 3
8 6.79 0.11 30.61 4.11 3
9 6.81 0.06 29.39 4.77 3
10 6.79 0.14 37.90 5.87 3
11 6.09** 0.56 29.75 7.22 3
12 6.44* 0.03 38.46 5.14 3
13 7.03 0.14 25.09 1.99 3











AM2	was	 profiled	 (Figure	 1.11B).	 Dose-response	 curves	were	 generated	 by	 normalising	 the	 peak	



















Figure	 3.10.	 Intracellular	 calcium	 signalling	 in	 HUVECs	 in	 response	 to	 the	 CGRP	 peptide	 family.	
Characterisation	 of	 i[Ca
2+
]	 release	 in	 response	 to	 stimulation	 by	 Ionomycin	 at	 10	 µM	 (A).	
Characterisation	 of	 i[Ca
2+




the	 cognate	 ligand	 (AM)	 and	 determined	 using	 one-way	 ANOVA	 with	 Dunnett’s	 post-hoc	 test,	 (*,	
p<0.05;	**,	p<0.01;	***,	p<0.001;	****,	p<0.0001).	 




µM	 ionomycin.	 Data	 are	 analysed	 using	 a	 three-parameter	 non-linear	 regression	 curve,	 and	 are	
presented	here	as	mean	±	S.E.M.	of	n	individual	data	sets.	pEC50:	negative	logarithm	of	the	agonist	
concentration	 required	 to	 produce	 a	 half-maximal	 response.	 Emax:	maximal	 response	 to	 ligands	
expressed	as	 a	 percentage	of	 ionomycin.	 pKa:	negative	 logarithm	of	 the	 equilibrium	dissociation	
constant	for	each	ligand	generated	using	the	operational	model	of	agonism	(Black	and	Leff	1983).	
Log!:	 coupling	 efficiency	 parameter	 of	 the	 ligand	 (Black	 and	 Leff	 1983).	 Statistical	 significance	
compared	to	the	cognate	ligand	(AM)	and	determined	using	one-way	ANOVA	with	Dunnett’s	post-
hoc	test,	(*,	p<0.05;	**,	p<0.01;	***,	p<0.001;	****,	p<0.0001).	 
	   Calcium	 	  
		 CGRP	 AM	 AM2	
pEC50	 5.44**	 0.33	 6.47	 0.26	 7.48*	 0.10	
Emax	 2.26****	 0.54	 34.72	 3.71	 66.36***	 2.66	
pKa	 5.44	 0.34	 6.29	 0.27	 7.03*	 0.10	
logt	 -1.63****	 0.10	 -0.28	 0.07	 0.29****	 0.05	
n	 3	 10	 10	
 







































































donor	 to	assess	whether	 the	 same	patterns	of	 responses	 could	be	 seen	across	 all	 three	 signalling	
































	 activation	 and	 i[Ca
2+
]	 release	 in	 response	 to	
stimulation	by	CGRP,	AM	and	AM2	in	HUVECs	relative	to	forskolin	(100	µM),	PMA	(100	µM)	and	




	   cAMP	 	  
		 CGRP	 AM	 AM2	
pEC50	 5.68***	 0.20	 7.93	 0.34	 6.82*	 0.30	
Emax	 17.85****	 4.83	 42.19	 1.61	 35.40	 1.10	
n	 6	 6	 9	
	       
   pERK1/2	 	  
		 CGRP	 AM	 AM2	
pEC50	 7.45**	 0.13	 6.29	 0.22	 5.76	 0.09	
Emax	 36.24	 2.18	 28.20	 2.07	 26.54	 2.72	
n	 3	 3	 3	
	       
   Calcium	 	  
		 CGRP	 AM	 AM2	
pEC50	 N/D	 N/D	 6.37	 0.64	 8.27**	 0.11	
Emax	 N/D	 N/D	 38.87	 2.80	 47.61***	 4.22	






























































over	 time.	 Moreover,	 for	 compounds	 over	 the	 concentration	 range	 used,	 purely	 looking	 at	 the	
baseline	 fluorescence	 of	 the	 cells	 treated	 with	 different	 concentrations	 there	 is	 no	 detectable	
concentration	dependent	effects:	This	is	shown	by	attempts	to	apply	a	non-linear	curve	fit	to	the	data	
(Figure	3.12	E,F).	It	was	possible	that	either	insufficient	NO	was	produced	over	the	time	range	used	





with	 L-Arginine	 which	 was	 done	 alongside	 ACh	 (Figure	 3.13A).	 15	 min	 was	 decided	 upon	 as	 the	
optimum	stimulation	time	as	it	was	at	this	point	that	ACh,	positive	control	for	GPCR	mediated	NO,	




















oxide	 release	 in	 response	 to	 stimulation	 by	 acetylcholine,	 ATP,	 forskolin	 and	 adrenaline	
respectively	 with	 continuous	 fluorescence	 recording	 for	 5min	 after	 stimulation	 (A-D).	 Multiple	
concentrations	were	used	and	displayed	as	10^X	M.	Data	are	analysed	using	a	three-parameter	
non-linear	regression	curve	(E-F).	 










































































































































parameter	non-linear	 regression	curve.	 Individual	pEC50	values	+	S.E.M.	are	 then	plotted.	 All	
values	are	calculated	from	at	least	3	individual	data	sets.		
 
Table	 3.9.	 	 Nitric	 oxide	 signalling	 in	 HUVECs	 in	 response	 to	 the	 CGRP	 peptide	 family.	
Characterisation	of	Nitric	oxide	release	in	response	to	stimulation	by	CGRP,	AM	and	AM2	relative	
to	100	µM	ACh.	Data	are	analysed	using	a	three-parameter	non-linear	regression	curve,	and	are	
presented	 here	 as	 mean	 ±	 S.E.M.	 pEC50:	 negative	 logarithm	 of	 the	 agonist	 concentration	
required	 to	 produce	 a	 half-maximal	 response.	 Emax:	 maximal	 response	 expressed	 as	 a	
percentage	 of	 NO.	 pKa:	 negative	 logarithm	of	 the	 equilibrium	 dissociation	 constant	 for	 each	







































































































	   NO	 	  
		 CGRP	 AM	 AM2	
pEC50	 5.73	 0.23	 6.29	 0.24	 6.88	 0.14	
Emax	 21.13	 2.89	 31.92	 4.25	 82.10***	 4.62	
pKa	 5.64	 0.52	 6.08	 0.31	 6.15	 0.15	
logt	 -0.59	 0.18	 -0.33	 0.11	 0.65**	 0.09	












provided	 the	 anti-proliferative	 control	 showing	 strong	 inhibition	 of	 cell	 proliferation.	 With	 these	
controls	established	CGRP,	AM	and	AM2	effects	were	then	explored.	Here	it	was	observed	that	CGRP	
was	 strikingly	 pro-proliferative	 (Figure	 3.14B).	 While	 there	 was	 a	 dose-response	 relationship	
detectable	 for	 AM	 and	 AM2	 in	 the	 pro-proliferative	 direction	 the	maximal	 levels	 of	 proliferation	
achieved	were	106.9%	and	103.7%	respectively	(Table	3.10)	and	therefore	only	marginally	over	100%.	





anti-proliferative	effects	 seen	 for	 forskolin	 it	 is	 interesting	 to	observe	 that	CGRP,	 the	 least	 potent	















100	 pM	 to	 100	 µM	 48	 h	 prior	 to	 detection	 and	 relative	 to	 vector	 control	 treated	 cells	 (A).	
Characterisation	of	cell	proliferation	in	response	to	stimulation	by	CGRP,	AM,	and	AM2	in	HUVECs	










maximal	 response	 to	 ligands	 expressed	 as	 a	 percentage	of	 VEGF.	 pKa:	 negative	 logarithm	of	 the	
equilibrium	dissociation	constant	for	each	ligand	generated	using	the	operational	model	of	agonism	
(Black	 and	 Leff	 1983).	 Log!:	 coupling	 efficiency	 parameter	 of	 the	 ligand	 (Black	 and	 Leff	 1983).	
Statistical	significance	compared	to	the	cognate	ligand	(AM)	and	determined	using	one-way	ANOVA	
with	Dunnett’s	post-hoc	test,	(*,	p<0.05;	**,	p<0.01;	***,	p<0.001;	****,	p<0.0001).	 
	   Proliferation	 	  
		 CGRP	 AM	 AM2	
pEC50	 8.00*	 0.19	 5.73	 0.68	 7.06	 0.90	
Emax	 140.39****	 2.13	 106.90	 3.47	 103.74	 1.43	
pKa	 7.69	 0.19	 5.69	 0.70	 7.03	 0.90	
logt	 0.02**	 0.06	 -0.95	 0.22	 -1.29	 0.20	
n	 5	 5	 5	
 


































































































order	 of	 potencies	 was	 CGRP>AM>AM2	 (Figure	 3.15C)	 exactly	 mirroring	 the	 HUVECs	 scenario	








and	 107.69±1.03)	 in	 contrast	 to	 CGRP	 which	 stimulated	 a	 potent	 and	 large	 (7.55±0.19	 and	




CALCR,	 CALCRL,	 RAMP1,	 RAMP2,	 and	 RAMP3	 genes	 in	 HUAECs	 determined	 by	 RT-PCR	 (A).	 Data	
represent	mean	 +	 SEM	 of	 three	 independent	 experiments	 relative	 to	 GAPDH	 expression.	 ND	 =	 not	
detected	in	all	 three	samples.	Characterisation	of	cAMP	accumulation	relative	to	forskolin	(100	µM)	
(B).	 Characterisation	 of	 intracellular	 calcium	 mobilisation	 (C)	 relative	 to	 ionomycin	 (10	 µM).	
Characterisation	of	 total	 nitric	oxide	production	 (D)	 relative	 to	 acetylcholine	 (100	µM).	 Intracellular	
ERK1/2	phosphorylation	(E)	relative	to	PMA	(10	µM).	Characterisation	of	cell	proliferation	(F)	relative	to	
vector	 treated	 control.	All	pathways	measured	 in	response	 to	stimulation	by	CGRP,	adrenomedullin	
(AM)	and	adrenomedullin	2	(AM2),	with	the	addition	of	forskolin	(FSK)	and	VEGF	for	cell	proliferation.	
Data	are	analysed	using	a	three-parameter	non-linear	regression	curve.	All	data	represent	mean	+	SEM	



















































































































































































































































































































































































































































	 activation	 signalling	 pathways,	 nitric	 oxide	 release	 and	 cell	
proliferation	 physiological	 responses	 in	 HUAECs.	 Data	 are	 analysed	 using	 a	 three-
parameter	 non-linear	 regression	 curve,	 and	 are	 presented	here	 as	mean	±	 S.E.M.	 of	 n	
individual	data	sets.	pEC50:	negative	logarithm	of	the	agonist	concentration	required	to	
produce	 a	 half-maximal	 response.	 Emax:	 maximal	 response	 to	 ligands	 expressed	 as	 a	
percentage	of	positive	control.	pKa:	negative	 logarithm	of	 the	dissociation	constant	 for	
each	ligand	generated	using	the	operational	model	of	agonism	(Black	and	Leff	1983).	Log!:	
coupling	efficiency	parameter	of	the	ligand	(Black	and	Leff	1983).	Statistical	significance	
compared	 to	 the	 cognate	 ligand	 (AM)	 and	 determined	 using	 one-way	 ANOVA	 with	
Dunnett’s	post-hoc	test,	(*,	p<0.05;	**,	p<0.01;	***,	p<0.001;	****,	p<0.0001). 
	 	 HUAEC	
	 	 CGRP	 AM	 AM2	
cAMP	
pEC50	 5.80***	 0.27	 7.12	 0.16	 6.76	 0.20	
Emax	 17.51*	 2.46	 24.97	 1.51	 17.46*	 1.21	
pKa	 5.72***	 0.28	 6.95	 0.14	 6.78	 0.21	
Logt	 -0.74*	 0.09	 -0.52	 0.03	 -0.75*	 0.05	
n	 10	 10	 10	
	 	 	 	 	 	 	 	
	 	 CGRP	 AM	 AM2	
iCa	
pEC50	 5.96	 0.14	 5.92	 0.17	 7.92****	 0.14	
Emax	 3.36****	 0.29	 50.35	 4.95	 50.11	 3.22	
pKa	 5.95	 0.14	 5.65	 0.19	 7.61****	 0.13	
Logt	 -1.46****	 0.04	 -0.01	 0.08	 -0.01	 0.05	
n	 3	 10	 10	
	 	 	 	 	 	 	 	
	 	 CGRP	 AM	 AM2	
pERK	
pEC50	 7.06	 0.18	 6.64	 0.15	 5.65*	 0.21	
Emax	 24.23*	 1.62	 16.48	 0.94	 17.59	 2.44	
pKa	 6.99	 0.13	 6.66	 0.21	 5.43*	 0.33	
Logt	 -0.52	 0.03	 -0.75	 0.05	 -0.67	 0.12	
n	 3	 3	 3	
	 	 	 	 	 	 	 	
	 	 CGRP	 AM	 AM2	
NO	
pEC50	 5.43	 0.39	 5.85	 0.09	 7.00*	 0.18	
Emax	 43.25	 13.02	 66.07	 2.63	 71.48	 4.88	
pKa	 5.10	 0.56	 5.41	 0.30	 6.47	 0.14	
Logt	 -0.09	 0.28	 0.28	 0.13	 0.40	 0.07	
n	 3	 3	 3	
	 	 	 	 	 	 	 	
	 	 CGRP	 AM	 AM2	
Growth	
pEC50	 7.55	 0.19	 11.45	 3.48	 9.93	 0.52	
Emax	 146.65****	 2.99	 102.63	 1.30	 107.69	 1.03	
pKa	 7.44	 0.39	 11.27	 6.72	 9.73	 1.44	
Logt	 -0.35	 0.07	 -1.76	 0.72	 -1.27	 0.20	









and	 RAMP1	were	 expressed	 at	 a	 detectable	 level	 in	 the	 HCMs	 (Figure	 3.16A).	 In	 the	majority	 of	
recombinant	 studies	 the	 CLR/RAMP1	 is	 known	 as	 the	 ‘CGRP	 receptor’	 and	 has	 been	 considered	
primarily	a	Gas	coupled	receptor.	Therefore,	an	intracellular	cAMP	accumulation	assay	was	again	used	




CGRP,	 AM	 and	 AM2	 in	 demonstrating	 the	 CLR/RAMP1	 in	 HCMs	 can	 couple	 to	 Gas	 to	 produce	 a	
detectable	 response.	Adding	 confidence	 to	 the	building	 evidence	 that	 the	CLR/RAMP1	 receptor	 is	
formed	in	these	cells,	and	as	CGRP	is	the	most	potent	ligand	at	cAMP	accumulation	followed	by	AM2,	










Figure	 3.16:	 Receptor	 expression,	 and	 CGRP	 family	 Peptide	 cAMP	 accumulation	 in	 Human	
Cardiomyocytes	 (HCMs).	 Expression	 of	 CALCR,	 CALCRL,	 RAMP1,	 RAMP2,	 and	 RAMP3	 genes	 in	
HCMs	 (A)	 Based	on	densitometry	 analysis	 of	 RT-PCR	 (Supplemental	 Figure	8.1).	 Data	 represent	
mean	+	SEM	of	three	independent	experiments	relative	to	GAPDH	expression.	Characterisation	of	









































































































As	 in	 the	HUVECs	 it	was	 important	 to	confirm	 the	cAMP	responses	observed	were	due	 to	 the	
suspected	 receptor,	 for	 all	 three	 ligands.	 This	 was	 confirmed	 using	 well	 established	 antagonists;	




































































































































































































Figure	 3.17.	 Antagonism	 of	 cAMP	 signalling	 in	 HCMs	with	 CLR-RAMP2	 and	CLR	
RAMP1	 antagonists.	 Characterisation	 of	 cAMP	 accumulation	 in	 response	 to	
stimulation	by	CGRP,	adrenomedullin	(AM)	and	adrenomedullin	2	(AM2)	in	HCMs	in	

















was	 not	 the	 case	 in	 HCMs	 where	 AM2	 was	 ostensibly	 the	 most	 potent	 although	 no	 parameters	
significantly	 differed	 from	 each	 other	 (Table	 3.12)	 and	 the	 dose-response	 curves	 almost	 overlaid	





















oxide	 production	 (B)	 relative	 to	 acetylcholine	 (100	 µM).	 Intracellular	 ERK1/2	 phosphorylation	 (C)	
relative	to	PMA	(10µM).	Characterisation	of	cell	proliferation	(D)	relative	to	vector	treated	control.	
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a	 percentage	 of	 positive	 control.	 pKa:	 negative	 logarithm	 of	 the	 equilibrium	
dissociation	 constant	 for	 each	 ligand	 generated	 using	 the	 operational	 model	 of	
agonism	(Black	and	Leff	1983).	Log!:	coupling	efficiency	parameter	of	the	ligand	(Black	
and	 Leff	 1983).	 Statistical	 significance	 compared	 to	 the	 cognate	 ligand	 (CGRP)	 and	
determined	 using	 one-way	 ANOVA	 with	 Dunnett’s	 post-hoc	 test,	 (*,	 p<0.05;	 **,	
p<0.01;	***,	p<0.001;	****,	p<0.0001).	 
	 	 HCM	
	 	 CGRP	 AM	 AM2	
cAMP	
pEC50	 8.39	 0.12	 5.84****	 0.08	 6.73****	 0.10	
Emax	 62.91	 1.85	 63.05	 3.14	 61.04	 2.50	
pKa	 8.05	 0.09	 5.38****	 0.19	 6.29****	 0.14	
Logt	 0.20	 0.03	 0.22	 0.10	 0.18	 0.06	
n	 10	 6	 6	
	 	 	 	 	 	 	 	
	 	 CGRP	 AM	 AM2	
iCa	
pEC50	 9.30	 0.10	 8.25*	 0.17	 8.17*	 0.33	
Emax	 64.44	 1.73	 58.12	 2.79	 36.50***	 2.31	
pKa	 8.85	 0.15	 8.10	 0.15	 7.91	 0.35	
Logt	 0.22	 0.05	 0.08	 0.04	 -0.30***	 0.05	
n	 3	 3	 3	
	 	 	 	 	 	 	 	
	 	 CGRP	 AM	 AM2	
pERK	
pEC50	 6.99	 0.11	 7.75*	 0.14	 5.66**	 0.17	
Emax	 33.02	 1.52	 40.13	 2.02	 40.41	 4.17	
pKa	 6.77	 0.15	 7.52*	 0.12	 5.52**	 0.18	
Logt	 -0.33	 0.04	 -0.19	 0.03	 -0.20	 0.08	
n	 3	 3	 3	
	 	 	 	 	 	 	 	
	 	 CGRP	 AM	 AM2	
NO	
pEC50	 6.27	 0.23	 6.37	 0.27	 6.87	 0.11	
Emax	 49.97	 5.56	 46.98	 5.85	 50.59	 2.18	
pKa	 -5.99	 0.22	 -6.07	 0.22	 -6.55	 0.18	
Logt	 0.01	 0.08	 -0.03	 0.08	 0.03	 0.06	
n	 3	 3	 3	
	 	 	 	 	 	 	 	
	 	 CGRP	 AM	 AM2	
Growth	
pEC50	 5.32	 1.80	 7.08	 0.23	 6.48	 0.58	
Emax	 108.80	 24.20	 160.32*	 6.82	 114.68	 3.58	
pKa	 5.23	 1.90	 6.45	 0.33	 6.38	 0.59	
Logt	 -0.65	 0.80	 0.52	 0.20	 -0.60	 0.12	






























Figure	 3.19.	 Signalling	 bias	 of	 the	
CGRP	family	of	peptides	in	HUVECs,	
HUAECs,	 and	 HCMs.	 Signalling	 bias	





for	 each	 agonist	 and	 for	 each	
signalling	pathway.	Determination	of	
values	 requires	 normalisation	 to	 a	
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causes	 almost	 double	 the	 maximal	 level	 of	 release,	 again	 compared	 to	 AM.	 Demonstrating	 the	
presence	of	agonism	bias	through	the	endogenous	CLR-RAMP2	receptor	and	suggesting	interesting	








also	 express	 CLR-RAMP2	 alone	 and	 show	 remarkable	 similarities	 to	 HUVECs	 with	 rank	 order	 of	
potencies	for	the	stimulating	peptides	mirroring	the	peptides	acting	in	HUVECs	almost	exactly.	There	





















In	 the	 previous	 chapter	 HUVECs	 were	 established	 as	 a	 model	 for	 studying	 endogenous	 CLR	
function	in	primary	human	cells,	and	observed	robust	cAMP	accumulation	reflective	of	a	canonical	Gs	
response	 indicative	 of	 CLR-RAMP2.	 Although	 having	 said	 that	 it	 is	 not	 known	 how	 much	 Gi	
involvement	 there	 is	 in	 the	 cAMP	 response	 observed.	 Alongside	 this	 cAMP	 accumulation	 data,	
interesting	signalling	responses	were	recorded	in	a	number	of	other	pathways,	the	source	of	which	is	
much	less	certain.	For	ERK1/2	phosphorylation	it	was	traditionally	considered	a	downstream	product	
of	 b-arrestin	 recruitment.	 However,	 there	 have	 been	 many	 other	 studies	 showing	 at	 least	 some	
degree	of	activation	from	GPCR	pathways.	Therefore	the	intention	was	to	use	established	inhibitors	
of	 different	 pathways	 and	 effectors	 to	 attempt	 to	 narrow	 down	where	 the	 ERK1/2	 activation	was	
generated	from	and	if	these	changes	depending	on	the	stimulating	ligand.	When	measuring	calcium	
release	 the	 experimental	 conditions	 were	 setup	 such	 that	 the	 only	 available	 calcium	 was	 from	
intracellular	sources.	This	gave	the	confidence	to	hypothesise	that	the	intracellular	signalling	was	Gq/11	
and	IP3	mediated,	and	it	was	attempted	to	confirm	this	using	the	selective	Gq/11	inhibitor	YM-254890.	








stimulated	by	a	 specific	 concentration	of	 ligand.	 In	order	 to	explore	 temporal	 cAMP	signalling	 the	
assay	has	been	modified	where	the	endpoint	is	adjusted	so	that	for	each	assay	it	a	time	between	0	
and	30	min	(the	normal	assay	endpoint),	moreover	IBMX	has	been	omitted	to	observe	natural	fluxes	
in	 cAMP	 level	 to	 build	 up	 and	 overall	 picture	 of	 temporal	 cAMP	 signalling.	 Combining	 this	 with	









CLR-RAMP2	 the	 ‘AM	 receptor’	 and	 CLR-RAMP1	 the	 ‘CGRP	 receptor’	 respectively.	 In	 order	 to	
interrogate	the	source	of	certain	signalling	pathways	further	it	was	important	to	first	establish	the	G	
protein	and	b-arrestin	expression	of	these	primary	cells	and	establish	which	of	these	proteins	they	
expressed.	 mRNA	 expression	 was	 explored	 through	 the	 use	 of	 RT-PCR	 which	 was	 able	 to	 show	
whether	 each	 component	was	 or	was	 not	 present	 at	 the	mRNA	 level.	 Densitometry	 analysis	was	






























































































































































































































































































































































































































































































































































































































































































































































































































alongside	 control	 experiments	 and	 assessing	 the	 statistical	 difference	 between	 control	 and	 PTX	
treated	 responses.	 In	 both	 cAMP	 and	 pERK1/2	 accumulation	 assays	 there	was	 no	 effect	 from	 PTX	
treatment	the	cognate	ligand,	AM,	induced	signalling	(Figure	4.2).	Whereas	there	was	for	the	other	

















































































































































































Figure	 4.2.	 cAMP	 and	 ERK1/2	 signalling	 in	 HUVECs	 with	 and	 without	 PTX	 treatment.	
Characterisation	 of	 cAMP	 accumulation	 and	 ERK	 phosphorylation	 in	 response	 to	
stimulation	by	CGRP,	AM	and	AM2	in	HUVECs	in	the	presence	and	absence	of	200	ng/ml	
PTX.	 Pre-treated	 for	 16	 h	 with	 PTX/Control.	 All	 relative	 to	 100	 µM	 forskolin	 or	 PMA	
respectively.	 Data	 are	 analysed	 using	 a	 three-parameter	 non-linear	 regression	 curve.	
Statistical	 significance	 determined	 compared	 to	 control	 using	 an	 unpaired	 t	 test	 with	
Welch’s	correction	(*,	p<0.05;	**,	p<0.01;	***,	p<0.001	****,	p<0.0001).	NS	denotes	no	
statistical	significance	observed.	All	values	are	calculated	from	at	 least	3	individual	data	












of	 cAMP	 accumulation	 in	 response	 to	 stimulation	 by	 CGRP,	 adrenomedullin	 (AM)	 and	
adrenomedullin	 2	 (AM2)	 in	 HUVECs	 in	 the	 presence	 and	 absence	 of	 200	 ng/ml	 PTX.	 Control	
treatment	is	denoted	by	(c).	Pre-treated	for	16	h	with	PTX/Control.	All	relative	to	100	µM	forskolin	
or	PMA	respectively.	Data	are	analysed	using	a	three-parameter	non-linear	regression	curve,	and	are	
presented	 here	 as	 mean	 ±	 S.E.M.	 of	 n	 individual	 data	 sets.	 Statistical	 significance	 determined	
compared	to	each	individual	control	using	an	unpaired	t	test	with	Welch’s	correction:	*,	p<0.05;	**,	
p<0.01;	***,	p<0.001. 
	   cAMP	+	PTX	 	  
		 CGRP	 AM	 AM2	
pEC50	 7.67***	 0.15	 8.01	 0.05	 7.71*	 0.09	
Emax	 19.43	 0.98	 56.50	 0.94	 50.59*	 1.26	
pEC50	(c)	 5.86	 0.19	 7.97	 0.09	 7.20	 0.19	
Emax	(c)	 19.82	 2.30	 55.31	 1.61	 39.23	 2.76	
n	 5	 5	 5	
	       
   pERK1/2	+	PTX	 	  
		 CGRP	 AM	 AM2	
pEC50	 6.20***	 0.18	 6.03	 0.12	 6.09	 0.13	
Emax	 26.76	 2.24	 27.31	 2.02	 18.51*	 1.27	
pEC50	(c)	 7.76	 0.10	 6.06	 0.10	 5.72	 0.21	
Emax	(c)	 34.58	 1.09	 35.75	 1.73	 33.45	 4.20	

























































































































































































































































































and	 YM254890	 (Gqi)	 respectively.	 Pre-treated	 for	 30	 min	 with	 inhibitor/Control.	 All	
relative	to	100	µM	PMA.	Data	are	analysed	using	a	three-parameter	non-linear	regression	
curve.	Statistical	 significance	determined	compared	 to	control	using	an	unpaired	 t	 test	
with	Welch’s	correction	(*,	p<0.05;	**,	p<0.01;	***,	p<0.001	****,	p<0.0001).	NS	denotes	
no	statistical	significance	observed.	All	values	are	calculated	from	at	least	3	individual	data	
















limitations	 and	 as	 it	 produced	 the	 greatest	 response	 and	 therefore	 largest	window	 for	 observing	
inhibitor	effects	 (Figure	4.4B).	The	adenylyl	 cyclase	 inhibitor:	SQ22536	and	PKA	 inhibitor:	Rp-8-Br-
cAMPs	were	used	to	see	whether	the	NO	was	a	result	of	Gs	and	cAMP,	however	neither	had	any	effect	
on	 the	maximal	 level	 of	 NO	 production.	Whereas	 the	 NOS	 inhibitor	 knocked	 down	 the	 response	
completely	verifying	that	the	NO	measured	was	indeed	coming	from	NOS.	Further	to	this	complete	











due	 to	Gq/11	 signalling	 it	 seemed	plausible	 that	 the	 same	could	be	 the	 case	 for	HCMs,	 indeed	 this	







Figure	 4.4.	 Inhibitor	 effects	 on	 i[Ca
2+	
]	 and	 NO.	 Characterisation	 of	 intracellular	 calcium	
mobilisation	with	and	without	YM-254890	relative	to	Ionomycin	(10	µM)	(A).	Characterisation	
of	AM2	mediated	Nitric	Oxide	release	with	and	without	Rp-8-Br-cAMPs,	SQ22536,	L-NAME,	and	






















































































































































Figure	4.5.	 Inhibitor	 effects	on	 i[Ca
2+	
]	and	NO.	Characterisation	of	
intracellular	 Calcium	 mobilisation	 with	 and	 without	 YM-254890	
relative	 to	 ionomycin	 (10	 µM)	 (A).	 Characterisation	 of	 nitric	 oxide	
release	 with/without	 YM-254890	 relative	 to	 Ach	 (10	 µM)	 (B).	



























































































at	 the	 endogenous	 CLR-RAMP2	 in	 HUVECs.	 Barbadin	 is	 a	 reported	 inhibitor	 of	 the	b-arrestin-AP2	




suggesting	 there	 was	 no	 effect	 of	 barbadin	 on	 AM	 cAMP	 accumulation	 response;	 confirmed	 by	
statistical	analysis	of	the	pEC50	and	Emax	values.	The	effect	of	barbadin	on	CGRP	seemed	to	suggest	
prevention	 of	 internalisation	 could	 enhance	 CGRP	 mediated	 cAMP	 signalling.	 This	 and	 the	





signalling,	which	 is	particularly	pronounced	 in	AM	(but	not	seen	at	all	 for	CGRP)	before	reaching	a	
plateau	of	sorts	by	8/10min,	and	cAMP	 ligands	 in	the	presence	of	each	of	 the	3	 ligands	remaining	
relatively	 constant	 until	 the	 assay	 endpoint	 at	 30	 min	 (Figure	 4.5).	 The	 same	 experiments	 were	
performed	 in	 the	 presence	 of	 barbadin.	 The	 overall	 shape	 of	 the	 response	 remained	 the	 same,	



















































































































































































































































































































































































Figure	 4.6.	 Barbadin	 effects	 on	 cAMP	 accumulation	 and	 time-course	 for	 cAMP	
accumulation	 in	 HUVECs.	 Characterisation	 of	 cAMP	 accumulation	 with	 and	 without	
barbadin	(100	µM)	In	response	to	stimulation	by	CGRP	(A),	AM	(B)	and	AM2	(C).	relative	
to	forskolin	(10	µM).	Characterisation	of	cAMP	accumulation	in	response	to	the	3	peptides	
at	 10	 µM	 over	 time	 (D)	 relative	 to	 forskolin	 (10	 µM).	 Characterisation	 of	 cAMP	
accumulation	 in	 response	 to	 the	 3	 peptides	 over	 time	 (E)	 in	 the	presence	of	 barbadin	
relative	to	forskolin	(10	µM).	Statistical	significance	determined	compared	to	control	using	







These	two	possible	phases	of	the	response	provided	 impetus	to	explore	this	 in	more	detail	 (in	
terms	of	full	dose-response	experiments).	Therefore,	the	effect	of	multiple	internalisation	inhibitors	
on	CGRP,	AM	and	AM2	signalling	responses	were	observed	at	different	time	points:	8	or	30	min,	with	




















































































































































































































































































































































































































































































































































































































































Figure	 4.7.	 Internalisation	 inhibitor	 effects	 on	 cAMP	 accumulation	 and	
time-course	for	cAMP	accumulation	in	HUVECs.	Characterisation	of	cAMP	






presented	 here	 as	 mean	 ±	 S.E.M.	 of	 4	 individual	 data	 sets.	 Statistical	





Next,	 how	 these	 inhibitors	 influenced	 the	 responses	 after	 30min	 stimulation	 without	 PDE	
inhibition	(no	IBMX)	was	studied	and	at	a	much-reduced	stimulation	time	of	8min	with	and	without	
PDE	inhibition	(Figure	4.8)	to	assess	whether	there	was	a	temporal	component	to	the	signalling	and	
whether	PDE	 inhibition	was	masking	 any	of	 these	potential	 spatiotemporal	 aspects.	At	 the	30min	
time-point	the	significant	barbadin	effect	on	CGRP	pEC50	remained	however	the	increases	produced	
by	the	other	inhibitors	were	not	significant.	Likewise,	there	was	again	no	effect	from	any	on	AM	or	




for	any	of	 the	peptides	at	any	of	 the	measured	parameters.	However,	moving	across	 to	 the	8min	
stimulation	time	experiments	there	is	a	noticeable	effect	from	the	inhibitors	on	CGRP	potency,	and	in	
one	 case	 the	 Emax	 increases.	 In	 terms	of	 significance	only	 barbadin	 and	 compound	101	 reach	 an	
























































































































































































































































































































































Figure	 4.8.	 Internalisation	 inhibitor	 effects	 on	 cAMP	 accumulation	 and	 time-course	 for	 cAMP	
accumulation	 in	 HUVECs.	 Characterisation	 of	 cAMP	 accumulation	 with	 and	 without	 barbadin	








Table	 4.2.	 Internalisation	 inhibitor	 effects	 on	 cAMP	 accumulation	 and	 time-course	 for	 cAMP	
accumulation	in	HUVECs.	Characterisation	of	cAMP	accumulation	with	and	without	barbadin	(100	
µM),	 dynasore	 (100	 µM),	 pitstop2	 (100	 µM),	 and	 compound	 101	 (100	 µM),	 In	 response	 to	





	   30mins	+	IBMX	 	  
Control	 CGRP	 AM	 AM2	
pEC50	 6.00	 0.15	 7.84	 0.15	 6.95	 0.18	
Emax	 108.68	 8.83	 101.31	 4.94	 95.76	 7.44	
Span	 105.62	 9.06	 98.89	 5.67	 99.80	 8.24	
n	 4	 	 4	 	 4	 	
       
+	barbadin	 CGRP	 AM	 AM2	
pEC50	 6.81*	 0.22	 7.41	 0.18	 8.05***	 0.11	
Emax	 96.27	 8.46	 115.06	 7.58	 90.83	 2.82	
Span	 92.25	 9.49	 102.50	 8.39	 93.36	 3.62	
n	 4	 4	 4	
	       
+dynasore	 CGRP	 AM	 AM2	
pEC50	 6.80	 0.36	 7.83	 0.15	 6.69	 0.14	
Emax	 95.59	 10.81	 119.41	 6.93	 140.35***	 7.69	
Span	 86.17	 11.79	 111.65	 7.87	 138.79**	 8.52	
n	 4	 4	 4	
	       
+pitstop2	 CGRP	 AM	 AM2	
pEC50	 6.84*	 0.16	 7.62	 0.14	 7.41	 0.14	
Emax	 123.72	 7.46	 133.78*	 7.68	 140.60***	 6.06	
Span	 108.73	 8.29	 122.94	 8.25	 137.82**	 7.42	
n	 4	 4	 4	
	       
+compound101	 CGRP	 AM	 AM2	
pEC50	 6.85*	 0.20	 7.95	 0.12	 7.52	 0.15	
Emax	 85.87	 7.03	 128.72*	 4.90	 103.39	 5.38	
Span	 87.76	 7.67	 125.58	 6.25	 104.26	 6.29	
n	 4	 4	 4	
 
	   30mins	no	IBMX	 	  
Control	 CGRP	 AM	 AM2	
pEC50	 5.98	 0.31	 7.52	 0.35	 6.66	 0.22	
Emax	 113.33	 17.66	 93.36	 11.46	 100.51	 9.54	
Span	 116.58	 17.77	 93.13	 13.02	 98.76	 10.16	
n	 4	 4	 4	
	       
+	barbadin	 CGRP	 AM	 AM2	
pEC50	 7.58**	 0.17	 7.70	 0.25	 7.05	 0.18	
Emax	 129.54	 6.48	 101.68	 10.52	 102.19	 8.66	
Span	 115.42	 7.71	 111.78	 12.63	 100.59	 9.28	
n	 4	 		 4	 		 4	 		
	       
+dynasore	 CGRP	 AM	 AM2	
pEC50	 6.75	 0.23	 7.80	 0.26	 7.26	 0.32	
Emax	 147.52	 14.78	 104.24	 11.26	 88.21	 11.83	
Span	 145.62	 15.97	 112.56	 13.76	 87.35	 12.85	
n	 4	 		 4	 		 4	 		
	       
+pitstop2	 CGRP	 AM	 AM2	
pEC50	 6.78	 0.25	 7.81	 0.25	 7.09	 0.21	
Emax	 127.20	 13.30	 101.65	 10.58	 114.72	 9.42	
Span	 122.50	 14.42	 117.10	 12.98	 111.55	 10.58	
n	 4	 		 4	 		 4	 		
	       
+compound101	 CGRP	 AM	 AM2	
pEC50	 6.52	 0.30	 8.05	 0.29	 7.05	 0.32	
Emax	 121.37	 13.44	 101.95	 13.67	 106.50	 14.14	
Span	 113.92	 14.14	 129.64	 16.78	 108.59	 15.82	
n	 4	 		 4	 		 4	 		
 
	   8	mins	+	IBMX	 	  
Control	 CGRP	 AM	 AM2	
pEC50	 7.00	 0.26	 6.91	 0.15	 6.84	 0.29	
Emax	 102.35	 10.95	 100.80	 6.01	 91.60	 11.22	
Span	 101.36	 12.19	 96.79	 6.63	 89.49	 12.28	
n	 4	 4	 4	
	       
+	barbadin	 CGRP	 AM	 AM2	
pEC50	 7.01	 0.26	 6.87	 0.17	 6.35	 0.25	
Emax	 120.07	 12.75	 105.39	 7.35	 91.71	 10.91	
Span	 118.82	 14.22	 101.56	 8.07	 88.49	 11.25	
n	 4	 4	 4	
	       
+dynasore	 CGRP	 		 AM	 		 AM2	 		
pEC50	 6.66	 0.25	 6.85	 0.09	 6.37	 0.13	
Emax	 124.14	 13.26	 118.12	 4.22	 101.27	 6.15	
Span	 120.20	 14.14	 114.55	 4.63	 99.06	 6.35	
n	 4	 4	 4	
	       
+pitstop2	 CGRP	 		 AM	 		 AM2	 		
pEC50	 6.79	 0.21	 6.73	 0.09	 6.21	 0.18	
Emax	 114.14	 9.99	 101.07	 3.94	 115.95	 10.41	
Span	 110.98	 10.86	 97.67	 4.24	 112.32	 10.67	
n	 4	 4	 4	
	       
+compound101	 CGRP	 		 AM	 		 AM2	 		
pEC50	 7.08	 0.28	 7.24	 0.22	 6.84	 0.14	
Emax	 83.43	 10.12	 88.59	 7.09	 74.37	 4.55	
Span	 90.44	 11.94	 83.28	 8.05	 74.55	 4.98	
n	 4	 4	 4	
 
	   8	mins	no	IBMX	 	  
Control	 CGRP	 AM	 AM2	
pEC50	 6.74	 0.24	 7.60	 0.43	 6.57	 0.30	
Emax	 104.05	 9.03	 95.06	 9.98	 96.37	 12.11	
Span	 106.89	 9.88	 68.32	 11.83	 91.95	 12.82	
n	 4	 4	 4	
	       
+	barbadin	 CGRP	 AM	 AM2	
pEC50	 7.87*	 0.26	 7.36	 0.24	 7.53	 0.21	
Emax	 167.10*	 17.67	 114.15	 8.86	 92.77	 6.67	
Span	 161.61	 18.39	 104.80	 10.55	 93.41	 7.81	
n	 4	 4	 4	
	       
+dynasore	 CGRP	 AM	 AM2	
pEC50	 6.85	 0.24	 7.63	 0.20	 6.49	 0.21	
Emax	 131.03	 12.87	 110.51	 5.50	 114.35	 10.67	
Span	 138.94	 14.59	 82.55	 6.65	 111.68	 11.17	
n	 4	 4	 4	
	       
+pitstop2	 CGRP	 AM	 AM2	
pEC50	 7.37	 0.29	 7.39	 0.24	 6.48	 0.22	
Emax	 112.98	 11.04	 105.52	 6.68	 113.65	 10.69	
Span	 111.65	 12.70	 77.08	 7.68	 108.03	 11.13	
n	 4	 4	 4	
	       
+compound101	 CGRP	 AM	 AM2	
pEC50	 8.26**	 0.35	 7.28	 0.35	 7.92*	 0.45	
Emax	 92.45	 11.56	 97.95	 10.50	 55.70*	 7.83	
Span	 100.01	 14.71	 82.62	 12.31	 51.37	 9.79	





Parallel	 to	 this	 in-depth	 analysis	 at	 specific	 time	 points	 more	 time	 course	 experiments	 were	
performed	 to	 see	 if	 there	 were	 observable	 changes	 to	 the	 natural	 pattern/shape	 of	 the	 cAMP	
response	(Figure	4.9).	Looking	at	CGRP	alone	alongside	treatment	+	barbadin	or	+	compound	101	it	is	
interesting	that	over	the	course	of	30	min	the	inhibitor	containing	time-courses	produce	slightly	larger	
responses	 in	 terms	 of	 amount	 of	 cAMP	 correlating	 with	 the	 dose-response	 data.	 In	 contrast	 the	
inhibitor	containing	time	courses	for	AM	and	AM2	seem	to	overlay	the	control	time-course,	with	the	
notable	exception	of	 the	 sharp	 initial	 peak	 for	AM	which	 is	 ablated	by	 compound	101	 treatment.	
















































































































































































































































































































































































































































































































































































































































































































































































































conformation	 that	 multiple	 Gi/o	 proteins	 were	 expressed	 in	 the	 HCMs	 (Figure	 4.1)(Supplemental	
Figure	8.2)	It	was	assessed	whether	there	was	a	Gi/o	component	to	CGRP,	AM	and	AM2	cAMP	signalling	
at	 the	 CLR-RAMP1	 in	 HCMs.	 In	 each	 case	 PTX	 pre-treatment	 caused	 little	 or	 no	 change	 in	 cAMP	
accumulation	compared	to	control	(Figure	4.11).	This	was	confirmed	through	statistical	analysis	of	the	







































































































PTX/Control.	 All	 relative	 to	 100	 µM	
forskolin.	Data	are	analysed	using	a	three-
parameter	 non-linear	 regression	 curve.	
Statistical	 significance	 determined	
compared	 to	 control	 using	 an	 unpaired	 t	
test	with	Welch’s	correction	(*,	p<0.05;	**,	
p<0.01;	***,	p<0.001	 ****,	p<0.0001).	NS	
denotes	 no	 statistical	 significance	
observed.	All	values	are	calculated	from	at	
least	 3	 individual	 data	 sets.	 Horizontal	









the	 internalisation	 inhibitor	 CGRP	 signalling	 is	 significantly	 supressed	 (Figure	 4.12A).	 Interestingly	
however,	none	of	the	other	ligands	are	significantly	affected	by	the	presence	of	barbadin	in	terms	of	
cAMP	signalling	(Figure	4.12A).	Then	the	pERK1/2	response	of	the	three	peptides	was	profiled	with	and	













barbadin	 (10	 0µM)	 In	 response	 to	 stimulation	 by	 CGRP,	 AM	 and	 AM2.	 relative	 to	
forskolin	 (100	µM)	and	PMA	(10	µM)	respectively.	Statistical	 significance	determined	
compared	 to	control	using	an	unpaired	 t	 test	with	Welch’s	 correction	 (*,	p<0.05;	 **,	
p<0.01;	***,	p<0.001	****,	p<0.0001).	NS	denotes	no	statistical	significance	observed.	







































































































































































































inhibitor	 completed	 knocked	 out	 signalling	 but	 that	 many	 pathways	 contribute	 to	 the	 pERK1/2	
response.	While	 these	data	disputes	 the	 assumption	 that	b-arrestins	 are	 the	 sole	 source	of	GPCR	
mediated	pERK1/2	activation	it	does	not	rule	out	the	possibility	that	they	provide	some	of	the	response	








It	was	hypothesised	 that	 removal	of	PDE	 inhibition	would	enhance	all	 internalisation	 inhibitor	
effects.	As	it	would	allow	the	natural	breakdown	of	cAMP,	if	internalisation	did	halt	signalling.	Then	





































with	cardiac	 fibroblasts	 (Chapter	2).	 It	was	hypothesised,	based	on	previous	work	here	 in	primary	
proliferating	cardiac	myocytes,	that	CGRP,	AM	and	AM2	may	influence	cardiac	function	to	differing	
extents	 and	 that	 this	 might	 be	 detectable	 as	 effects	 on	 cardiac	 beat	 rate.	 Therefore,	 it	 was	 first	
attempted	 to	 confirm,	 in	 the	 author’s	 hands,	 the	 successful	 functioning	 of	 assays	 for	 intracellular	
calcium	and	beat	rate	in	2D	as	well	as	beat	rate	studies	in	3D;	before	moving	to	study	the	influence	of	
CGRP	family	peptides	on	the	function	of	cardiac	myocytes	in	these	assays.	











HUVEC	 cells	 could	 be	 established	 the	 purpose	 of	 re-expressing	 a	 different	 RAMP	 (RAMP1)	 was	
twofold:	The	first	was	to	demonstrate	that,	if	it	could	rescue	CLR	signalling	function,	gene	editing	that	
had	led	to	a	loss	of	CLR	signalling,	had	done	so	through	affecting	RAMP2	gene	expression	exclusively.	
Therefore,	 if	 RAMP	 re-expression	 rescued	 receptor	 function	 this	 could	 confirm	 there	 were	 no	
detrimental	off	target	effects.	Secondly,	by	re-expressing	a	RAMP	different	from	the	endogenous	one,	

















































to	 isoproterenol	 (100	 nM)	 and	 control	 treatment	 (A).	 Percentage	 increase	 in	 beat	 rate	 in	
response	 to	 Isoproterenol	 and	 relative	 to	 control	 treatment	 at	 multiple	 time	 points	 (B).	
Statistical	significance	determined	compared	to	control	using	an	unpaired	t	test	with	Welch’s	
correction	 (*,	 p<0.05;	 **,	 p<0.01;	 ***,	 p<0.001	 ****,	 p<0.0001).	NS	denotes	 no	 statistical	
significance	observed.	All	values	are	calculated	from	4	individual	data	sets.	 
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three	 ligands	 cause	 the	 beat	 rate	 to	 rise	 above	 level	 reached	 in	 the	 control	 cell	 assays	 and	 then	
maintain	a	higher	beat	rate	for	the	duration	of	the	assays.	Plotting	selected	time	points	as	percentage	
increase	 over	 baseline	 shows	 subtle	 differences	 between	 the	 peptide	 responses	 (Figure	 5.2D-F).	
Firstly,	it	shows	that	at	the	peak	response	the	order	of	magnitude	of	response	is	AM2>AM>CGRP	with	
CGRP	producing	a	response	that	is	not	significantly	greater	than	control	as	determined	by	statistical	
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to	 Isoproterenol	 and	 Control	 treatment.	 Measurement	 of	 IPSC	 derived	 icell	 human	














difference.	Here	 is	plotted	 the	 three	parameters	 recorded:	 calcium	peak	width,	 rate	and	size.	The	
FLIPR	 (fluorescent	 imaging	plate	 reader)	 system	 is	able	 to	 record	 the	 intrinsic	 intracellular	calcium	
spikes	that	occur	within	the	icell	myocytes,	and	this	can	then	be	measured	and	reported	as	a	‘Peak	
rate’	 -	 the	number	of	 calcium	peaks	over	 a	 given	 time	 interval.	 It	 also	 records	 the	width	of	 these	






















Statistical	 significance	 determined	 compared	 to	 control	 using	 an	 unpaired	 t	 test	 with	Welch’s	
correction	 (*,	 p<0.05;	 **,	 p<0.01;	 ***,	 p<0.001	 ****,	 p<0.0001).	 NS	 denotes	 no	 statistical	
significance	observed.	All	values	are	calculated	from	4	individual	data	sets.	 

















































































































































































8.4).	 Immediately	 it	was	 clear	 they	 all	 influenced	 the	 calcium	 fluxes	within	 the	myocytes	 through	
decreasing	the	peak	width,	increasing	peak	rate	and	increasing	peak	size.	However	in	comparing	the	
percentage	 changes	 over	 control	 at	 different	 time-points	 (Figure	 5.5,6,7;A)	 this	 reveals	 subtle	
differences	between	the	peptide	effects	on	intracellular	calcium.	Taking	changes	in	the	calcium	peaks	
first	while	none	of	CGRP,	AM,	or	AM2	produced	significant	 increases	over	 the	control	at	any	 time	
point,	of	the	three	CGRP	stimulated	the	highest	calcium	peaks.	Moving	on	to	calcium	peak	frequency,	
at	 their	 peak	 all	 three	 peptides	 stimulated	 a	 statistically	 significant	 increase	 over	 control	 (Figure	
5.5,6,7;B).	Although	of	these	the	CGRP	was	the	smallest	and	appeared	the	most	biphasic	(Figure	5.5A):	
The	 peak	 rate	 dropped	 quickly	 after	 the	 peak	 before	 rising	 back	 up	 by	 the	 end	 of	 the	 assay.	 In	
comparison	AM	and	AM2	produced	sustained	rises	in	peak	rate	throughout	the	assay,	of	the	two	AM2	
caused	the	greatest	increase.	By	the	assay	end-point	only	AM2	still	caused	a	significant	increase	above	

































































































































































































































































































































































































































































































































































































































































































































Welch’s	 correction	 (*,	 p<0.05;	 **,	 p<0.01;	 ***,	 p<0.001).	 NS	 denotes	 no	 statistical	 significance	
observed.	All	values	are	calculated	from	4	individual	data	sets.	 

































































































































































































































































































































































dose	 response	 curve	 was	 produced	 for	 the	 calcium	 peak	 frequency	 increases	 produced	 by	 the	
peptides	(Figure	5.8B).	Here	it	was	interesting	to	observe	that	AM2	produced	the	highest	maximal	
response	 (As	seen	 in	Figure	5.7A	above)	but	 the	 full	dose	 response	revealed	 that	CGRP	was	more	
potent	 at	 lower	 concentrations.	Moving	 onto	 the	 dose-response	 curve	 produced	 for	myocyte	 cell	











Figure	 5.8.	 icell	 cardiac	 myocytes	 Gene	 expression	 and	 CGRP	 family	 peptide	 dose-
response	 in	 cAMP	 accumulation,	 Ca
2+
	 peak	 rate,	 and	 peak	 beat	 rate.	 Expression	of	
CALCR,	CALCRL,	RAMP1,	RAMP2,	and	RAMP3	genes	in	icell	myocytes	determined	by	qRT-
PCR.	Data	represent	mean	+	SEM	of	three	independent	experiments	relative	to	GAPDH	
expression.	 ND	 =	 not	 detected	 in	 all	 three	 samples	 (A).	 Dose-response	 curves	 were	
constructed	 for	 myocytes	 stimulated	 with	 CGRP,	 AM	 or	 AM2	 and	 the	 cAMP	 levels	
quantified	 relative	 to	 forskolin	 (100	µM)	 (B),	 peak	 calcium	 rate	 produced	 relative	 to	
isoproterenol	 (100	 nM)	 (C),	 and	 the	 peak	 whole	 cell	 beat	 rate	 produced	 relative	 to	
isoproterenol	(100	nM)	(D).	All	data	represent	mean	+	SEM	of	at	least	three	independent	
experiments.	Data	are	analysed	using	a	three-parameter	non-linear	regression	curve.	 
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Figure	 5.9.	 Beat	 rate	 of	 icell	 cardiac	 myocytes	 grown	 in	 3D	 spheroids	 in	 response	 to	











Up	 to	 this	point	observations	of	 the	effects	of	CGRP,	AM	and	AM2	on	 iCell	beat	 rates	 in	a	2D	
system,	 the	3D	 system	 involves	a	3D	co-culture	 system	using	human	cardiac	 fibroblasts	 (Receptor	
expression	 and	 signalling	 responses	 to	 CGRP	 family	 peptides	 in	 (Supplemental	 Figure	 8.6).	 This	
enables	an	even	more	physiologically	relevant	study	of	peptide	effects	on	cardiac	function.	Having	
confirmed	 that	 positive	 effects	 could	 be	 observed	 on	 the	 intrinsic	 beat	 rate	 of	 the	 spheroids	 by	
isoproterenol	then	CGRP,	AM	and	AM2	were	tested	in	the	spheroid	model:	In	(Figure	5.10A)	all	three	
ligands	cause	the	beat	rate	to	rise	above	level	reached	in	the	control	cell	assays	and	then	maintain	a	
higher	beat	rate	for	the	duration	of	the	assays.	The	 increase	 is	to	a	 lesser	extent	than	the	positive	
control	isoproterenol.	Interestingly,	when	plotting	peak	and	final	beat	rates	as	percentage	increase	
over	baseline	this	shows	the	peptides	produced	their	greatest	effects	at	different	times	compared	to	
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(Hoechst)	 identified	 cell	 population.	 The	 initial	 antibiotic	 concentrations	 used	 were	 too	 high	 (2.5	


























































































Figure	 5.11.	 Kill	 curve	 generation	 in	 HUVECs	 with	 puromycin	 and	 blasticidin.	 Cells	 are	
plated	24	h	before	being	treated	with	either	puromycin	or	blasticidin	with	media/antibiotic	
changed	every	2	days.	A	range	of	10	concentrations	were	used:	2.5	µg/ml	to	30	µg/ml	(A-B)	
0.25	 µg/ml	 to	 5	 µg/ml	 (C-D)	 0.025	µg/ml	 to	 0.5	µg/ml	 (E).	 Cells	 were	 then	 imaged	 and	
counted	 before	 dose-response	 curves	 were	 constructed	 for	 each	 antibiotic	 and	








target	 the	 gene	 of	 interest	 (RAMP2).	 The	 supplier	 provided	 a	 vector	 targeted	 to	 the	 unrelated	
Hypoxanthine-guanine	phosphoribosyltransferase	(HPRT)	housekeeping	gene	(Figure	5.12A).	HUVECs	














The	 first	 was	 cell	 survival,	 whereby	 the	 virus	 clearly	 conferred	 antibiotic	 resistance,	 secondly	 it	
enabled	cellular	translation	of	the	cas9	protein,	and	thirdly	translation	of	GFP,	both	of	which	again	in	





















































































































the	 control)	 the	 virus	 could	 confer	 antibiotic	 resistance	 and	 lead	 to	 synthesis	 of	 cas9	 and	 GFP.	





resultant	DNA	was	 sent	 to	 Eurofins	 for	 Sanger	 sequencing,	 and	 Tide	 analysis	 revealed	 a	 knockout	
efficiency	of	39%.	This	was	not	sufficient	to	take	the	cells	forward	for	further	experiments.	Therefore	
the	 same	 experiments	 were	 performed	 and	 DNA	 amplification	 transducing	 the	 HUVECs	 with	 the	
highest	MOI	 that	 had	 been	 previously	 optimised	 for,	 which	 was	 an	MOI	 of	 10.	 Subsequent	 DNA	
extraction	and	Sequencing	revealed	a	knockout	efficiency	of	97.5%.	Further	confocal	images	were	also	
captured	to	demonstrate	the	extent	of	antibiotic	resistance	conferred	by	MOI	10	(Figure	5.14A-C)	(or	
not	 without	 viral	 transduction)	 and	 the	 extend	 of	 cas9	 and	 GFP	 production	 (Figure	 5.14D-F).	
Interestingly	 the	 localisation	 of	 these	 proteins	 can	 be	 seen;	 with	 cas9	 predominantly	 nuclear,	
reassuring	 as	 nuclear	 localisation	 is	 required	 for	 its	 function,	 and	 GFP	 seems	 predominantly	
cytoplasmic.	Further	to	this	the	extent	of	genomic	disruption	is	observable	in	the	chromatograms	of	















































































































































1	 of	 RAMP2	 gene	 containing	
sgRNA	 target	 sites	 for	 Control	
HUVECs	(A)	vs	same	section	in	
CRISPR-cas9	 KO	 HUVECs	 (B)	








These	RAMP2	knockout	HUVECs	were	 then	used	 to	observe	how	 the	knockout	 influenced	 the	
transcription	and	then	signalling	function	of	RAMP2.	Firstly,	the	qRT-PCR	experiments	performed	on	
these	cells,	in	these	experiments	RAMP2	mRNA	no	longer	appeared	above	detection	threshold	(Figure	
5.16A).	 This	 loss	of	RAMP2	 transcript	detection	 suggests	degradation	 through	nonsense-mediated	
mRNA	decay	(NMD).	Importantly	however	the	expression	of	CLR	remained,	suggesting,	at	the	mRNA	











all	 pathways	 measured	 were	 abolished	 (Figure	 5.16B-F).	 Demonstrating,	 unsurprisingly	 given	 the	
overwhelming	data	from	recombinant	studies,	that	without	a	RAMP	present	CLR	does	not	function	

























































































































































































































AM	 is	 the	 next	 most	 potent	 ligand,	 followed	 by	 AM2,	 making	 the	 rank	 order	 of	 potencies:	





































































































independent	 experiments	 relative	 to	 GAPDH	 expression.	 ND	 =	 not	 detected	 in	 all	 three	 samples.	
Characterisation	of	cAMP	accumulation	in	response	to	stimulation	by	CGRP,	AM,	and	AM2	in	RAMP1-
HUVECs	 relative	 to	 100	 µM	 forskolin	 (B).	 Data	 are	 analysed	 using	 a	 three-parameter	 non-linear	















3.18)	 in	 another	 primary	 cell:	 the	 human	 cardiac	myocytes	which	 also	 expressed	CLR-RAMP1	and	
there	too	the	 intriguing	ERK1/2	response	was	seen;	where	the	non-cognate	 ligand	displays	a	strong	
potency.	 Then	 in	 nitric	 oxide	 signalling	 all	 three	 ligands	 produce	 a	 response	with	 a	 rank	 order	 of	
potency:	 CGRP>AM>AM2	 (Figure	 5.18C),	 this	 order	 is	 identical	 to	 that	 of	 intracellular	 calcium	
signalling	mirroring	 a	 trend	 seen	 in	wild	 type	 HUVECs	 and	 HUAECs.	 Lastly	 all	 three	 peptides	 also	
promoted	cell	proliferation	(Figure	5.18D),	a	difference	from	all	previous	cell	models,	moreover	the	
potencies	were	less	distinct	from	one	another	–	none	were	statistically	different	from	CGRP	(Table	










































































































































	 activation	 signalling	 pathways,	 nitric	






relative	 to	 10	 µM	 acetylcholine	 (C).	 Characterisation	 of	 cell	 proliferation	 RAMP1-
HUVECs	relative	to	10	µM	VEGF	(D).	All	pathways	measured	in	response	to	stimulation	




	 		  HUVEC	RAMP1	
	  CGRP	 AM	 AM2	
cAMP	
pEC50	 9.03	 0.12	 7.43****	 0.17	 7.16****	 0.11	
Emax	 43.20	 1.29	 38.95	 2.08	 32.66**	 1.57	
pKa	 8.87	 0.11	 7.20****	 0.14	 6.97****	 0.16	
Logt	 -0.15	 0.02	 -0.22	 0.03	 -0.344**	 0.05	
n	 4	 4	 4	
	        
  CGRP	 AM	 AM2	
iCa	
pEC50	 7.90	 0.12	 7.24***	 0.09	 5.78****	 0.10	
Emax	 51.30	 2.06	 44.13*	 1.42	 40.46**	 2.26	
pKa	 7.52	 0.09	 6.97*	 0.10	 5.64****	 0.18	
Logt	 0.03	 0.03	 -0.10	 0.03	 -0.18**	 0.06	
n	 6	 6	 6	
	        
  CGRP	 AM	 AM2	
pERK	
pEC50	 6.62	 0.20	 7.47*	 0.08	 6.90	 0.14	
Emax	 38.69	 3.40	 47.57	 1.48	 45.35	 2.89	
pKa	 6.52	 0.17	 7.16*	 0.13	 6.56	 0.14	
Logt	 -0.19	 0.05	 -0.02	 0.04	 -0.06	 0.05	
n	 3	 3	 3	
	        
  CGRP	 AM	 AM2	
NO	
pEC50	 7.11	 0.16	 6.77	 0.19	 5.90**	 0.23	
Emax	 75.15	 4.51	 56.30	 4.50	 53.96	 7.60	
pKa	 6.54	 0.18	 6.43	 0.21	 5.51*	 0.29	
Logt	 0.47	 0.09	 0.11	 0.08	 0.08	 0.14	
n	 3	 3	 3	
	        
  CGRP	 AM	 AM2	
Growth	
pEC50	 6.07	 0.49	 6.77	 0.40	 5.85	 0.17	
Emax	 143.61	 12.20	 195.27*	 14.23	 201.29*	 11.45	
pKa	 5.89	 0.70	 5.84	 0.81	 5.02	 0.44	
Logt	 -0.09	 0.30	 1.10	 0.64	 0.71	 0.34	
n	 4	 4	 4	
 
Table	5.1.	pEC50,	Emax,	pKa,	and	 log	 tau	values	 for	 cAMP	accumulation,	 i[Ca
2+
]	
mobilisation	 and	 ERK1/2	 activation	 pathways,	 nitric	 oxide	 release	 and	 cell	
proliferation	physiological	responses	in	RAMP1-HUVECs.	Data	are	analysed	using	a	
three-parameter	 non-linear	 regression	 curve,	 and	 are	 presented	 here	 as	mean	 ±	
S.E.M.	 of	 n	 individual	 data	 sets.	 pEC50:	 negative	 logarithm	 of	 the	 agonist	
concentration	 required	 to	 produce	 a	 half-maximal	 response.	 Emax:	 maximal	
response	to	ligands	expressed	as	a	percentage	of	forskolin.	pKa:	negative	logarithm	
of	 the	 equilibrium	 dissociation	 constant	 for	 each	 ligand	 generated	 using	 the	
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bias	of	 h 	 RP	 family	
of	 p ptides	 in	 primary	
human	 c lls.	 Signalling	
bias	 plots	 were	






HUAECs	 (B),	 HCMs	 (C),	
and	HUVEC-RAMP1s	(D).	
Values	 are	 on	 a	
logarithmic	 scale	 for	




to	 a	 reference	 agonist	


















producing	 four	 separate	 cell	 type	 comparisons	 (Figure	 5.2A-D).	 Firstly,	 analysis	 of	 the	 correlation	
between	 peptide	 agonist	 potency	 in	 RAMP1-HUVECs	 and	 HCMs	 for	 the	 five	 different	 signalling	
pathways	 revealed	 a	 positive	 correlation:	 (r	 =	 0.55	 (95%	 confidence	 interval,	 0.051	 to	 0.82;	 p	 <	
0.05)(Figure	 5.20A)	 showing	 	 how	 closely	 aligned	 the	 signalling	 properties	 in	 RAMP1-HUVECs	 and	
HCMs	are.	In	contrast,	when	performing	the	same	analysis	of	the	correlation	between	HUVECs	and	
HCMs	 (Figure	 5.20B),	 and	 then	HUVECs	 and	 RAMP1-HUVECs	 there	was	 no	 detectable	 correlation	
(Figure	5.20C).	 In	both	 these	comparisons	one	cell	 type	expresses	CLR-RAMP1	and	 the	other	CLR-
RAMP2.	Lastly	for	the	two	wild-type	endothelial	cells	(HUVECs	and	HUAECs),	where	there	was	a	strong	
similarity	in	the	bias	plots	across	the	five	different	pathways.	This	was	then	further	supported	by	a	















































































































































































































































































































































































































































































































































































































































































































































95% confidence interval -0.70 to 0.256
N.S.
AM2












































95% confidence interval -0.826 to -0.044
p<0.05 p=0.036
AM2












































































95% confidence interval -0.70 to 0.256
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95% confidence interval -0.826 to -0.044
p<0.05 p=0.036
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95% confidence interval -0.70 to 0.256
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95% confidence interval -0.826 to -0.044
p<0.05 p=0.036
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95% confidence interval -0.70 to 0.256
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95% confidence interval -0.826 to -0.044
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95% confidence interval -0.826 to -0.044
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95% confidence interval -0.826 to -0.044
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95% confidence interval -0.826 to -0.044
p<0.05 p=0.036
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This	 chapter	 started	 with	 research	 designed	 to	 further	 explore	 whether	 the	 CGRP	 family	 of	
peptides	 were	 capable	 of	 differentially	 influencing	 physiologically	 relevant,	 functional	 cellular	
outcomes.	The	was	explored	through	assessing	their	 impact	on	 IPSC	derived	cardiac	myocyte	beat	
rates,	in	2D	and	3D	models,	and	intracellular	calcium	fluxes.	It	was	reported	that	all	three	peptides	
had	 a	 positive	 impact	 on	myocyte	 beat	 rate,	 but	 there	were	 subtle	 differences	 in	 their	 effects	 at	























as	 well	 as	 comparing	 the	 non-genetically	 altered	 primary	 cell	 types	 with	 each	 other	 bias	 and	













form	a	 high	 affinity	 receptor	 for	 CGRP	 through	 co-expression	with	RAMP1	 (AMY1R)	 (Walker	 et	 al.	
2015).	Therefore,	it	was	crucial	to	confirm	whether	CTR	was	present	in	the	primary	cells	of	interest	to	
ensure	 that	 the	CGRP	 response	observed	was	purely	 due	 to	CLR-RAMP	 receptor	 complexes	 not	 a	
mixed	population.	Furthermore,	 it	was	also	 important	to	discern	between	the	different	CLR-RAMP	
complexes	 was	 present	 in	 each	 cell	 as	 each	 receptor-RAMP	 complex	 forms	 unique	 and	 distinct	
receptors	with	their	own	signalling	properties	(Hay	et	al.	2003).	The	first	primary	cells	studied	included	
HUVECs	and	VSMCs.	Comparing	purely	their	receptor	expression	at	an	mRNA	level	both	expressed	

































































does	 this	 coupling	 exist	 in	 physiologically	 relevant	 cell	 systems,	 and	 to	 what	 end?	 It	 has	 been	
demonstrated	 that	 Gi,	 Gq,	 and	 pERK1/2	 (discussed	 further	 later)	 signalling	 as	 well	 as	 Nitric	 Oxide	
(discussed	 below).	 PTX	 was	 used	 as	 a	 known	 specific	 inhibitor	 of	 Gi	 proteins	 to	 assess	 their	
involvement	 in	 cAMP	 accumulation,	 and	 intracellular	 calcium	 fluxes	 as	 an	 indirect	measure	 of	 Gq	
protein	coupling,	but	also	in	combination	with	a	Gq	specific	inhibitor	which	was	able	to	directly	link	
calcium	release	to	Gq	protein	activity.	Gi	coupling	is	the	next	G	protein	revealed	here	to	directly	couple	
to	 the	CLR	 in	primary	HUVECs.	The	coupling	upon	stimulation	by	CGRP	 is	particularly	 interesting	–	
CGRP	is	weak	promoter	of	cAMP	accumulation	at	CLR-RAMP2	in	HUVECs	these	could	be	attributed	at	
first	 glance	 to	 a	 relative	 inability	 to	 recruit	Gs.	 However,	 the	 PTX	 revelation	 that	Gi	 inhibition	 can	
significantly	 increase	CGRP	mediated	 cAMP	production	 shows	 that	under	natural	 conditions	CGRP	
recruits	Gi	 proteins	 and	 actively	moves	 the	 receptor’s	 signalling	 away	 from	 cAMP	production	 and	
inhibits	adenylyl	cyclase.	Moreover,	 the	observation	that	PTX	also	 inhibits	the	CGRP	mediated	ERK	
response	suggests	that	the	purpose	of	Gi	recruitment	is	twofold:	to	suppress	cAMP	production	and	to	
promote	 ERK1/2	 phosphorylation	 this	 is	 also	 likely	 to	 be	 mediated	 separately	 by	 the	 G	 protein	







studies	 in	 the	 human	 cardiac	 myocytes	 revealed	 more	 interesting	 differences	 between	 the	 CLR-









knocking	 down	 this	 protein	 in	 the	 HUVEC	 system	 could	 be	 observed	 (Supplemental	 Figure	 8.8).	
Although	much	controversy	accompanies	the	discussion	of	RCP	as	it	is	also	a	component	of	human	
RNA	 polymerase	 III.	 Throwing	 into	 question	 the	 cause	 of	 effects	 seen	 from	 knockdown	 studies	
(Routledge	et	al.	2020).	
Further	 exploration	 of	 this	 ERK	 signalling	 in	 HUVECs	 suggested	 that	 ERK	 phosphorylation	 is	 a	
signalling	event	that	ultimately	multiple	pathways	may	converge	on.	This	is	a	concept	that	has	been	
explored	previously	(Belcheva	and	Coscia	2002).	The	contribution	that	Gi	makes	to	CGRP	mediated	


































































































Figure	 6.1.	 Representation	 of	 the	 signalling	 outcomes	 downstream	 of	 CLR-RAMP2	
stimulated	 by	 CGRP,	 Adrenomedullin	 or	 Adrenomedullin	 2	 in	 a	 HUVEC.	 Including	 G	
proteins	 known	 to	 couple	 to	 CLR-RAMP2	 and	 their	 signalling	 pathways	 as	 a	 result	 of	










dictating	 these	 roles	 are:	 NO	 and	 proliferation.	 NO	 is	 a	 direct	 mediator	 of	 vasodilation	 and	 an	
important	regulator	of	vascular	homeostasis	and	observing	cell	proliferation	 is	a	direct	measure	of	




vasodilation	 through	 direct	 actions	 of	 vascular	 smooth	 muscles	 cells	 or	 myocytes:	 acting	
predominantly	in	a	paracrine	manner,	it	diffuses	into	cardiac	myocytes	and	VSMCs	where	it	stimulates	
cGMP	production,	which	itself	activates	PKG	and	in	VSMCs.	This	kinase	reduces	vascular	tone,	VSMC	














Michel,	 and	 Balligand	 2018),	 and	 as	 both	 molecules	 are	 produced	 downstream	 of	 Gq	 it	 seems	















physiology	 of	 these	 endothelial	 cells	 that	 is	 unique	 from	 the	 other	 peptide	 agonists.	 As	 stated	
previously	the	Gs	coupling	to	the	CLR	and	any	of	the	RAMPs	has	been	well	studied	-	the	physiological	
importance	of	this	signalling	pathway	has	also	been	looked	at	in	some	detail	in	endothelial	cells,	with	
a	 report	 showing	 that	 AM	 is	 important	 for	 endothelial	 barrier	 stabilisation	 and	 protect	 against	
infection	 (S.	 aureus	a-toxin)	mediated	 loss	of	VE-cadherin,	 it	 also	blocked	 toxin	 related	 junctional	



































through	 the	 CLR-RAMP1	 receptor	 complex	with	 the	 use	 of	 the	 clinically	 approved	 CGRP	 receptor	
antagonist	Olcegepant.	This	then	enabled	the	research	to	explore	further	signalling	pathways	beyond	
cAMP:	one	of	which	was	Gq	mediated	 intracellular	 calcium	 release,	 all	 three	peptides	produced	a	
potent	response	but	CGRP	was	again	the	most	potent.	Then	there	was	Gq/11	mediated	NO	production,	




















failure	 because	 there	 is	 not	 enough	 cardiomyocyte	 regeneration,	 and	 ground-breaking	 work	 has	
demonstrated	 a	 low	 rate	 of	 	 innate	 regeneration	 in	 the	 heart	 (Bergmann	 et	 al.	 2009),	 and	much	
research	has	gone	 in	 to	attempts	 to	harness	 this	 in	 the	hope	of	 therapeutically	promoting	cardiac	
repair,	including	studies	into	the	potential	use	of	VEGF	(Taimeh	et	al.	2013).		
New	 and	 different	 approaches	 are	 needed	 as	 studies	 into	 the	 efficacy	 of	 stem	 cell	 or	 cardiac	
progenitor	 cell	 transplantation	 into	 the	damaged	heart	 have	not	been	 successful	 for	 a	number	of	
reasons.	Foremost	among	them	being	 they	were	not	able	 to	differentiate	engraft	and	survive	 in	a	
beneficial	 way.	 Nonetheless	 they	 were	 aided	 the	 failing	 heart	 through	 paracrine	 effects	 and	 the	
release	of	molecules	from	these	stem	cells(Maghin	et	al.	2020).	One	such	molecule	was	pregnancy-
associated	plasma	protein-A	(PAPP-A).	PAPP-A	was	demonstrated	to	instruct	vesicle	release	of	insulin-














replacement	 in	 normal	 mammalian	 hearts	 and	 after	 injury	 (Senyo	 et	 al.	 2013).	 Stimulation	 of	
cardiomyocytes	has	been	proposed,	and	is	currently	a	much	explored	therapeutic	strategy	(Becker	






design	 of	 small	 molecules	 that	 could	 mimic	 AM’s	 signalling	 bias	 to	 promote	 cardiomyocyte	
proliferation.	
Since	cardiomyocytes	comprise	only	about	20%	of	all	cells	within	the	human	myocardium	(Rubart	and	
Field	 2006).	 This	means	 the	 heart	 is	made	up	 of	many	 cell	 types	 including;	myocytes,	 fibroblasts,	
smooth	muscle	cells,	endothelial	cells	or	hematopoietic	cells,	this	makes	it	very	difficult	for	studies	of	
drug/hormone/peptide	overall	effect	on	heart	 function	 to	narrow	down	how	precisely	an	effect	 is	
brought	about.	Particularly	in	the	case	of	CGRP/AM/AM2.	This	is	further	complicated	by	observations	
of	the	vastly	different	receptor	composition	(Figure	6.2)	and	signalling	outcomes	these	peptides	have	
















Graphic	 showing	 cell	 types	 making	 up	 the	 human	 heart	 and	 their	 respective	 mRNA	








continues	 to	 signal	 from	within	 the	endosome	 (Yarwood	et	 al.	 2017).	 The	 internalisation	 inhibitor	
barbadin	(Beautrait	et	al.	2017)	was	used	to	explore	the	role	of	internalisation	on	CGRP	family	peptide	
signalling	in	the	primary	cell	models.	In	the	case	of	the	HCMs	and	CGRP	mediated	cAMP,	barbadin	










results	were	 varied,	 for	 instance	 in	 terms	of	AM	 signalling	 there	were	no	 cases	where	 any	of	 the	
inhibitors	 could	 influence	 AM	 signalling.	 This	 suggests	 that	 the	majority,	 if	 not	 all	 of	 AM’s	 cAMP	
production	through	the	CLR-RAMP2	receptor	occurs	at	the	cell	surface.	All	inhibitors	tested	at	at	least	
one	condition	were	able	to	influence	AM2,	whereby	they	were	able	to	increase	the	cAMP	produced	











been	 much	 work	 to	 suggest	 that	 pERK1/2	 signalling	 occurs	 intracellularly	 and	 downstream	 of	 b-



























and	 how	 the	 peptide	 effects	 directly	 compare	 to	 one	 another.	 Using	 spontaneously	 beating	 IPSC	
derived	myocytes	the	direct	effects	of	CGRP,	AM	and	AM2	on	myocyte	beat	rate	were	investigated	in	






early	and	 late	phase	of	 the	 response.	This	difference	was	 then	enhanced	at	24	h	where	 the	CGRP	
mediated	increase	was	even	greater.	In	order	to	see	whether	these	effects	were	mediated	through	a	












responses	also	produced	some	 interesting	differences	compared	 to	other	pathways	and	cell	 types	




peptides	 produce	 interesting	 and	 varied	 effects	 on	 beating	 myocytes	 were	 the	 3D	 spheroid	
experiments	where	similar	rank	orders	of	magnitude	were	seen	in	terms	of	peak	and	final	responses.	
























its	 endogenous	 function.	But	with	 the	 caveat	 that	 in	order	 to	 truly	 compare	how	 the	RAMP	 itself	


















the	 signalling	 bias	 in	 HUVECs	 either	 expressing	 RAMP1	 or	 RAMP2	 emphasised	 the	 remarkable	
influence	 the	 single	 transmembrane	 RAMP	 has	 on	 CLR	 signalling:	 Using	 CGRP	 as	 an	 example	 the	
peptide	shows	strong	bias	towards	pERK1/2	and	proliferation	at	the	CLR-RAMP2,	but	then	at	the	CLR-
RAMP1	 its	 bias	 profile	 is	 completely	 switched	 such	 that	 it	 is	 now	 biased	 towards	 cAMP	 and	
intracellular	calcium	mobilisation	
Using	primary	cells	however	does	have	 its	 limitations,	most	prominent	among	 them	 is	 the	 limited	




of	good	antibodies	 targeting,	GPCRs	such	as	 the	CLR	and	 the	RAMPs	specifically	 (Hay	et	al.	2018).	
Indeed	 there	 are	 two	 commercial	 antibodies	 that	 were	 recently	 designed	 for	 use	 in	
Immunofluorescence,	but	when	it	was	attempted	to	optimise	them	for	use	in	this	study	they	did	not	
appear	very	selective	for	one	RAMP	over	another	(Supplemental	Figure	8.9)	
A	 potential	 downside	 of	 the	 CRISPR-cas9	 mediated	 gene	 editing	 and	 re-expression	 of	 RAMP1	 in	
HUVECs	is	that	it	involves	the	creation	of	an	artificial	expression	system.	Something	there	was	a	strong	





patterns	 observed	 back	 to	 the	 bias	 seen	 in	 HCMs	 endogenously	 expressing	 RAMP1.	 As	 well	 as	
analysing	how	the	responses	from	each	peptide	at	each	pathway	correlated	with	each	other	in	the	






























































































































































to	have	protective	effects	 in	heart	 failure.	Using	models	of	heart	 failure	work	could	 look	at	which	
pathways	contribute	to	this	protection	with	the	aim	of	therapeutically	targeting	them	in	the	future.		
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Control CGRP AM AM2
Supplemental	 Figure	 8.4.	 Example	 raw	 calcium	 release	 traces.	 These	 traces	 show	 a	
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Expression	 of	 CALCR,	 CALCRL,	 RAMP1,	 RAMP2,	 RAMP3,	 HPRT1	 and	 NOS3	 genes	












RAMP1-HUVECs.	 Statistical	 significance	 calculated	 using	 a	 one	 way	 Anova	 in	
comparison	 to	 the	 control	 (WT-HUVECs)	 for	 each	 day.	 Only	 RAMP1-HUVECs	
demonstrated	significance	on	the	indicated	days. 





























































































































































































Supplemental	 Figure	 8.8.	 Influence	 of	 RCP	on	 endogenous	CLR	 signalling	 in	 HUVECs:	 RT-PCR	 Gel	









































































































































































































































































and	 qRT-PCR.	 Optimisation	 of	
a	 range	 of	 manufacturer	
suggested	 dilutions	 of	
antibodies	 for	 human	 RAMP1	
and	 RAMP2	protein	 in	 HUVEC	
and	 PC3	 cells.	 Cells	 treated	
with	RAMP1	or	RAMP2	protein	
antibody,	and	Hoechst	nuclear	
stain	 imaged	 using	 20x	
objective	 with	 both	
fluorescence	channels	overlaid	
(A).	 Analysis	 of	 mean	
fluorescence	
intensity/cell/well	 for	 each	
antibody	 	 over	 a	 range	 of	
concentrations	 in	 HUVECs	 (B),	
and	 PC3	 (C)	 data	 represent	
mean	 +	 SEM	 of	 three	
independent	 experiments.	
Expression	 of	 CALCR,	 CALCRL,	
RAMP1,	 RAMP2,	 RAMP3,	
HPRT1,	 and	 NOS3	 genes	
determined	 by	 qRT-PCR	 in	
HUVECs	 (D)	 and	 PC3	 cells	 (E).	
Data	represent	mean	+	SEM	of	
three	 independent	
experiments	relative	to	GAPDH	
expression.	ND	=	not	detected	
in	all	three	samples. 
